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The purpose of this quality improvement project is to compare the provider’s 
perception following an educational model of using single symptom management versus 
multi-symptom management during the end-of-life transition in adult patients for 
improved quality of life outcomes.  The appraised evidence indicates that it is critical to 
have anticipatory medications at the patient’s residence to manage multiple symptoms 
rather than focusing exclusively on a single symptom management such as pain 
management.  In February 2016, the author conducted an educational model among 
hospice providers for increasing knowledge and awareness of multi-symptom 
management.  Thirty (n = 30) Clinical Nursing Directors, Licensed Practical Nurses, 
Medical Directors, and Registered Nurse Case Managers from hospice organizations 
located in South Carolina were surveyed pre and post intervention regarding their 
perception of symptoms, the most prominent distressful symptoms that are experienced 
by hospice patients, and the pharmaceutical preference to manage distressful symptoms.  
With a response rate of 77%; (n=23) participants pre-test responses indicated that pain 
(35%) was the most prominent symptom among patients; Dyspnea/SOB (44%) was 
identified as the most distressful symptom for patients; and anxiety/restlessness and 
increased respiratory secretions received (35%) as the most distressful symptoms for 
vi 
 
patients’ families and/ or caregivers witnessed during a patient’s last two weeks of life.  
Hospice provider’s post-test responses indicated that the most prominent symptom was 
dyspnea/SOB (30%) followed by pain (22%).  Additionally, the presence of 
anxiety/restlessness had increased by almost (10%) in the post-test results (26%).  
Healthcare providers reported the most distressful symptom for the patient was 
dyspnea/SOB (44%) with the same response rate both pre-test and post-test.  However, 
the prevalence of pain as the most distressful symptom’s response rate decreased from 
pre-test (17%) to post-test (9%).  The presence of perceived increased respiratory 
secretions response rate increased from pre-test (13%) to post-test (22%).  This project 
was consistent with the evidence that multi-symptom management is critical in end of life 
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Chapter 1 Introduction 
1.1 The Description of Clinical Problem   
Approximately 2.5 million people die annually in the United States, and 
approximately 1.05 million die in a palliative care or hospice care environment.  In 1967, 
the first modern hospice was established by Dame Cicly Saunders with the goal to 
improve the quality of life for dying people (Anderson & Chojnacka, 2012).  Hospice 
patients experience multiple symptoms in the terminal phase of the dying process, often 
impairing the quality of life during the end-of-life transition.  These symptoms include 
increased pain, secretions, nausea, dyspnea, and anxiety/restlessness.  The most 
problematic symptoms identified in the terminal phase of death are pain, anxiety, nausea, 
and increased respiratory tract secretions (Anderson & Chojnacka, 2012; Bishop, 
Stephens, Goodrich, & Byock, 2009; Sera, McPherson, & Holmes, 2014).  To improve 
the quality of life during the end-of-life transition, evidence indicates that it is critical to 
have anticipatory medications at the patient’s residence to manage multiple symptoms 
rather than focusing exclusively on pain management (Anderson & Chojnacka, 2012; 
Bishop et al., 2009; Wowchuk, Wilson, Embleton, Garcia, Harlos, & Chochinov, 2009).   
During the final days of the dying process, distressful symptoms, especially respiratory 
tract symptoms, can also emotionally impact the patient’s family and loved ones because 





on”; therefore, it is essential to encourage multi symptom management (Anderson & 
Chojnacka, 2012).  
The number of hospice patients and end-of-life operations have rapidly increased 
over the past several years.  According to the National Hospice and Palliative Care 
Organization in 2012, an estimated 1.5 to 1.61 million patients received services from 
hospice care and over 5,500 hospice programs exist across the nation (NHPCO, 2013).  
With an increased demand for hospice services, it is essential for healthcare providers to 
focus their attention on this vulnerable population and deliver best practice measures to 
improve their patients’ quality of life during the end-of-life transition.  Best practices 
warrant investigation and multi-symptom management for the improvement of hospice 
patients’ quality of life.  A continuously evolving healthcare milieu requires increased 
utilization and application of evidenced-based research for hospice care and end-of-life 
symptom management.  Applying knowledge is obligatory to implement interventions 
that promote optimal quality comfort measures experienced during the end-of-life 
transition.  Providing palliative care does not allow patients’ to elude death, rather it 
provides them with the autonomy for symptom management and to accept dying as a 
natural process that deserves complete dignity.  Increasing evidence-based research on 
multi-symptom management, and not just focusing on pain as the only distressful 
symptom that occurs during the terminal phase of death, is imperative.  The purpose of 
this quality improvement project is to compare the provider’s perceptions using an 
educational model of applying single symptom management versus multi-symptom 
management during the end-of-life transition in adult patients over 18 for improved 





1.2 Scope of problem 
 First, evidence shows that Hospice patients experience multiple symptoms, not 
just pain.  Sera et al. (2014) reported that the most prominent symptoms encountered in 
hospice patients at end-of-life were pain, dyspnea, nausea, delirium, anxiety, and 
depression.  These findings paralleled a study by Wowchuk et al. (2009) who reported 
that retained respiratory secretions and subsequent dyspnea, were the most common 
causes of distress experienced during the terminal phase by this vulnerable population.  
The study also demonstrated that the most prominent symptoms addressed in hospice 
patients were pain, nausea, vomiting, shortness of breath, agitation, confusion, retained 
respiratory secretions, and weakness (Wowchuk et al., 2009).  Johnson, Kassner, Houser, 
and Kutner (2005) identified that several studies in both hospice and non-hospice 
environments identified fatigue, not pain, as the most severe and distressful symptom 
experienced by terminally ill patients.   
Despite a myriad of symptoms experience by hospice patients at the end-of-life, 
hospice care continues to focus on pain management, leaving the other symptoms 
unaddressed.  According to Fleming, Sheppard, Mangan, Taylor, Tallarico, Adams, and 
Ingham (2006) as death approached in patients diagnosed with cancer, the psychological 
variables anxiety and depression become more significant than physical symptoms.  
Dying patients suffer from symptoms that are treatable, many experience serious pain; 
however, due to less research on other symptoms, evidence suggests a pattern of 
inadequate symptom management (Kutner, Kassner, & Nowels, 2001).  Barriers for 
effective symptom management differ among different groups of symptoms, symptom 





2005).  Quality of life is poor with single symptom management versus multi-symptom 
management.         
Secondly, data indicate that families experience distress with insufficient 
symptom management.   For example, Curtis, Patrick, Engelberg, Norris, Asp, and Byock 
(2002) identified the perspective of family members after the death of their loved one. 
Their evidence showed that family members reported anxiety among themselves in 
dealing with their loved one’s symptom management at the end-of-life.  There is a lack of 
research regarding the training or skills required by family caregivers to manage 
medications at home when dealing with multiple symptoms associated hospice patients 
during the end-of-life transition (Lau, Kasper, Hauser, Berdes, Chang, Berman, Masin-
Peters, Paice, & Emanuel, 2009).  According to Lau et al. (2009) evidence suggest that 
family caregivers feel inadequately prepared to manage hospice patient’s medication and 
symptom control.  Most family members are unknowledgeable on the subject of 
pharmaceutical regimens, they require education in medication and symptom 
management.  Kutner and colleagues (2001) addressed the need to prepare caregivers to 
administer immediate symptom relief by calling the hospice for directions and utilizing 
the symptom relief kit when a sudden decline in patient’s comfort becomes obvious.  The 
hospice nurse in one study actively discussed with the patient’s family members what to 
expect, what certain symptoms occurred, how to approach the management of particular 
symptoms, reduce anxieties, and decrease the occurrence of hospitalizations in the 
hospice patients population (Wowchuk et al., 2009).  A similar study demonstrated that 





by the hospice patients will be addressed within the established plan of care (Bishop et 
al., 2009).      
      Third, government accountability by CMS (2013) is now requiring that hospice 
and palliative care organizations utilize and report quality measures in end of life 
transition environments, otherwise, a reduction in reimbursement will occur for failure to 
comply.  With the evolving changes in the U.S. National healthcare reform, 
reimbursements and regulatory compliance changes from Centers for Medicare & 
Medicaid Services (CMS) should be an impetus for all hospice and palliative care 
organizations to utilize quality measures.  According to the CMS (2013), to avoid a 
reduction in the Annual Payment Determination in 2015, it has been a federal 
requirement for all hospice agencies as of March 3, 2014 to collect and submit data to 
CMS for two measures.  These methods include structural measures related to the content 
of their Quality Assessment and Performance Improvement (QAPI) program and the 
National Quality Forum (NQF) #0209 Pain Measure (CMS, 2013).  According to the 
CMS (2013) structural measures provides CMS with general information about the kinds 
of patient care related quality indicators (QIs) used in hospice organizations’ QAPI 
programs, an example of patient care related quality indicators may address topics such 
as symptom management (e.g., pain, dyspnea, nausea, anxiety, depression).  Moreover, 
CMS (2013) the NQF #0209 reflects the number of patients who report being 
uncomfortable because of pain at the initial assessment (after admission to hospice 
services) who report that pain was brought to a comfortable level within 48 hours of 
admission to hospice.  Steindal, Bredal, Sorbye, and Lerdal (2011) recommend electronic 





facilitate a thorough record of data identifying symptoms that occur in dying patients.  
CMS also reported that each hospice operation that cares for Medicare patients must 
submit data for both measures to CMS by the deadline April 1, 2014 to comply with 
reporting requirements (CMS, 2013).  These quality of life measures are important 
because they represent a holistic approach with multi symptom management, thus 
improve the end of life transition experience for patients and their families.         
      During the end-of-life transition symptoms and clinical signs in hospice patients 
serve as the basis for individualized multi-symptom management to improve quality of 
life (Steindal et al., 2011).  Morphine alleviates only two symptoms in hospice patients 
during the end-of-life transition, pain and dyspnea.  Steindal and colleagues (2011) 
support the management of multi-symptom management for facilitate improved 
outcomes for patients at the end-of-life transition. Federal agencies require multi-
symptom management for reimbursement.  Families are expecting multi-symptom 
management for end of life transition for loved ones.  A dilemma that family members 
face is the moral obligation to alleviate a patient’s suffering and the uncertainty regarding 
the best choice of symptom relief (Brown & Vaughan, 2013).   
1.3 Discussion of Practice Innovation/Best Practices to Address the Problem 
Evaluation of hospice patients during the terminal phase of dying is essential to 
address multi-symptom management.  Utilizing anticipatory multi-symptom interventions 
allow the patient’s symptoms to be relieved quickly, effectively, and results in improved 
outcomes and better standards of care (Anderson & Chojnacka, 2012; Kinley, Stone, & 





which medication or intervention can be delivered to yield the best patient outcome and 
alleviate the symptoms.  Comfort care kits or anticipatory medications are often used for 
hospice patients experiencing episodes of distressing multi-symptoms.   
When a patient experiences a symptom, the caregiver is able to administer a 
comfort medication after notifying the hospice agency first.  Comfort care kits contain 
medications that address multiple symptoms including pain, dyspnea, nausea/vomiting, 
anxiety/restlessness, agitation/delirium, noisy secretions, and fever.  The implementation 
of multi-symptom management guidelines best integrate standards of care in clinical 
practice for managing multiple symptoms and improving quality of life during end of life 
transition (Anderson & Chojnacka, 2012; Wowchuk, et al., 2009).   
1.4 Statement of problem/purpose 
  In adult hospice patients 18 years and over, how does the provider’s perception of 
using multi symptom management following an educational model compare to single 
symptom management medication improve overall quality of life during the end-of-life 
transition?  The Population (P) are providers managing adult patients in hospice care.  
The Intervention (I) is the implementation of multi symptom management educational 
module.  The Comparison (P) is the current practice of using single symptom 
management.  The Outcome (O) is effectively managing multi symptoms for improved 
quality of life during the end-of-life transition in adult patients over 18 in hospice.  The 
most common symptoms during the terminal phase of illness were documented as pain, 
sickness, agitation, and respiratory tract secretions (Anderson & Chojnacka, 2012).   





of-life transition include pain, excessive secretions, and terminal restlessness (Kinley 
et.al, 2013).  In this project the following symptoms will be examined: pain, dyspnea, 
increased secretions, and restlessness for quality of life outcomes.  The goal is to enhance 
comfort and promote the quality of life for individuals and their families during the end 
of life transition.          
Table 1.1: Evidence Based Practice Clinical Question 







Improved quality of 
life and symptom 
management during 
end of life 
transition in adult 
patients over 18 
years of age 
 
1.5 Project Questions 
 The project was guided by the following clinical questions: 
      Does the utilization of anticipatory medications prevent delays in symptom 
management during the dying phase?   
What medications alleviate pain best in patients during the end-of-life transition?  





What evidence identifies the best medications to use in hospice patients with 
dyspnea, respiratory distress, increased secretions, anxiety and/or restlessness?   
What type of educational support do providers and families need to best manage 
multi-symptoms of their loved ones in hospice care? 
What is the quality of life for patients and their families experiencing multi-
symptom management?   
1.6 Definitions 
      Hospice has been considered to be the model for quality, compassionate care for 
people facing a life-limiting illness or injury.  Hospice care involves a team-oriented 
approach to expert health care, pain management, and emotional and spiritual support 
expressly tailored to the patient's needs and wishes (National Hospice and Palliative Care 
Organization, 2013).  It has been essential for all hospice organizations to focus on 
maintaining the quality of life through symptom management, healthcare educational 
support, and ensuring that the patient’s dignity remains upheld during the difficult 
transition into death.  There may be a misconception that only patients with stage IV 
cancer or a prognosis of less than two weeks qualify for end-of-life care.  End-of-life care 
promotes and improves quality of life to patients whose physicians have given them a 
prognosis of six months or less to live.  According to the NHPCO (2010), hospice affirms 
the concept of palliative care as an intensive program that enhances comfort and 
promotes the quality of life for individuals and their families; furthermore, hospice 






 Hospice is defined as a model for quality, compassionate care for people facing a  
 
life-limiting illness that involves a team-oriented approach to expert health care,  
 
pain management, and emotional and spiritual support tailored to the individual  
 
patient’s and loved one’s needs and wishes (NHPCO, 2013).  Hospice focuses on  
 
caring, not curing terminally ill patients that have a prognosis of less than six  
 
months to live.   
 
 Adults are defined as individuals 18 years old and over.  
 End-of-life care is defined as the promotion and improvement in quality of life to 
imminent patients, rather than attempting to cure underlying disease in patients 
whose healthcare providers have given them a prognosis of six months or less to 
live.  End-of-life care requires a holistic approach for those suffering with life 
limiting illnesses. During this terminal phase of life patient’s wish to be 
comfortable, free of pain, and other symptoms (Klinkenberg, Willems, Wal, & 
Deeg, 2004).     
 Pain is defined as a subjective intolerable discomfort for patients triggered by the 
nervous system.  The onset of pain can occur acutely, intermittent, continuous, or 
chronic.  Pain is identified as one of the most common and distressing symptoms 
encountered in hospices patients receiving end-of-life care that medications can 
help alleviate (Rurup, Borgsteede, Heide, Maas, & Onwuteaka-Philipsen, 2009; 
Zerzan, Benton, Linnebur, O’Bryant, & Kutner, 2010).    
 Dyspnea is defined as difficulty breathing, shortness of breath, the feeling of 





 Increased secretion is defined as secretions that have settled in the upper airways 
and oropharynx.  Noisy, moist, bubbling breathing is heard and is considered an 
indicator that a person’s may be actively dying (Kinley et al., 2013; Kintzel, 
Chase, Thomas, Vancamp, & Clements, 2009).   
 Terminal restlessness is defined as signs of restlessness include tossing, turning, 
thrashing, agitation, involuntary muscle jerks, or moaning that can occur during 
the final days or hours for a person (Kinley et al., 2013). 
 Multi symptom management is defined as a focus on various discomforts, multi 
concurrent symptoms, or manifestations experienced by patients.   
 Comfort care kits is defined as  emergency kits containing anticipatory 
medications for uncontrolled pain, respiratory distress, restlessness, agitation, and 
nausea (Bishop et al., 2009).     
 Anticipatory Medications are medications ordered for a patient to ensure there is 
no delay in responding to any symptom that may occur during the end-of-life 
transition (Kinley et al., 2013).   
 Quality of life (QoL) is defined as the final common pathway for hospice care 
services where healthcare professional reflects an individual’s satisfaction with 
his/her current situation and has been defined as a sense of well-being concerning 
physical, psychological, social, and spiritual dimensions (Henoch, Bergman, 
Gustafsson, Gaston-Johansson, & Danielson, 2007).   
 Healthcare provider is defined as a doctor of medicine or osteopathy, podiatrist, 





who is authorized; holds a license to practice by the State to deliver patient care 
within their scope of practice as defined by their State’s law.   
 Family is defined as a group of individuals related by blood or affection.  
Members of families can include the following: parents, siblings, grandparents, 
aunts, uncles, cousins, or close friend that are considered a social unit.    
 Palliative care is defined as care aimed to improve the quality of life of patients 
and their families facing a life-limiting illness (Crang & Muncey, 2008).  
Palliative care is defined as the active total care of patients whose progressive 
disease is not responsive to curative treatment and the overall focus of health care 
delivery is quality of life (Conill, Verger, Henriquez, Saiz, Espier, Lugo, & 
Garrigos, 1997).    
 Dying is defined as imminent patients in the last days of life (Frechen, Zoeller, 
Ruberg, Voltz, & Gaertner, 2012).   
 Medication is defined as pharmacological interventions to relieve distressing 
symptoms (Lau, Kasper, Hauser, Berdes, Chang, Berman, Masin-Peters, Paice, & 
Emanuel, 2009). 
 Best Practice is defined as the application of the best available research results 
(evidence) when making decisions about health care and utilizing research 
evidence along with clinical expertise and patient preferences (U.S. Department 
of Health & Human Services, 2015).  
1.7 Chapter Summary     
      Hospice patients have a prognosis of six months or less to live; imminent death or 





dyspnea.  However, it does not address all the unexpected symptoms that occur with 
hospice patients during their final days.  Lau et al. (2009) identifies the cornerstone of 
hospice care has been the utilization of medications to relieve any symptoms.  In hospice 
patients, anticipatory multi-symptom medications will improve overall multi-symptom 
management and patient outcomes.  The delivery of care encompasses the utilization of 
evidenced-based best practice measures to alleviate multi-symptoms in hospice patients 
and quality of life during the end-of-life transition.  Anticipatory medications that address 
multiple symptoms at the patient’s residence can potentially improve overall symptom 
management during the end-of-life transition.  Effective symptom management is one of 
the many concepts necessary to improve hospice patient outcomes and allow the patient 
to experience a dignified death.  Implementation of comfort care kits into hospice 
patients’ homes can reduce suffering and distress by both patients and their caregivers 
during symptom crisis.  Continuous provider and caregiver education is imperative to 
understanding the symptoms and therapeutic interventions that can provide relief to 
hospice patients.  Identifying and appraising quality evidence from current research is 
important to change current clinical practice guidelines that lead to improved patient 
outcomes.  The goal of this quality improvement project is to improve the quality of life 











Chapter 2 Literature Review 
2.1 Search Methodology 
Our continuously evolving healthcare system sometimes uses evidence-based 
research to facilitate process improvement.  It is essential for healthcare clinicians to 
possess the skills of critically appraising evidence and distinguishing best evidence from 
unreliable evidence (Melnyk & Fineout-Overholt, 2011).  The purpose of this clinical 
quality improvement project is to compare the provider’s perceptions after an educational 
model for single-symptom management versus multi-symptom management during the 
end-of-life transition in adult patients to improve quality of life outcomes for a dignified 
death.  To that end, a systematic literature review was performed with the purpose of 
identifying evidence that supports the utilization of multi-symptom management, 
implementation of comfort care kits, best pharmacologic measures to alleviate multi 
symptoms, and interventions to improve the quality of care provided to hospice patients 
during their end-of-life transition.  This study used a comprehensive search of databases 
accessed through the University of South Carolina’s online library as the basis to identify 
comfort and quality interventions to address multi-symptom management in hospice 
patients during end-of-life care.  
The electronic databases utilized in the review were CINAHL, EBSCO, OVID, 
and PubMed.  This project used all databases for the advanced search of medical 





improved patient outcomes with medications, comfort care kits, or other interventions.  
This quality improvement project combined groups of key search terms and words 
tosearch each database.  The following search terms were utilized: “death” or “terminal 
care” or “hospice” or “end of life” or “dying” or “dying process” or “hospice care” or 
“palliative care” and “signs or symptoms” and “symptoms” and “pain” and “dyspnea” 
and “increased secretions” and “nausea” and “comfort care kits” and “medication kits” 
and “medications” and “caregivers” and “morphine” and “best practice”.  The limitations 
were set for English-only papers with additional criteria of the publication years to have 
occurred between the years 1997 through 2015.  This project implemented these 
limitations to generate current, up-to-date, and continuous research on specific end-of-life 
care interventions.  The search engine produced literature from topics on prominent 
symptoms, medications utilized to alleviate symptoms, comfort medication kits, 
pharmacovigilance, caregivers’ concerns/skills needed, and several articles that compared 
medications used in hospice patients.  The database generated significant data from 
selected articles placed in a literature review table (See Appendix F) then utilized for 
their analysis and synthesis.   
Hierarchies of research designs have been indicated as the best levels of evidence 
for this intervention type PICO question regarding multi-symptom management 
compared to single-symptom management using morphine medication only to improve 
overall quality of life during the end-of-life transition.  Levels of evidence to answer this 
type of question rank from highest to lowest in the following order: systematic 
review/meta-analysis of randomized control trials (RCT); nonrandomized control trials; 





qualitative or descriptive single studies; and expert opinions (Melnyk & Fineout-
Overholt, 2011).  This study rated quantitative and qualitative studies on their level of 
quality through application of the Scottish Intercollegiate Guidelines Network (SIGN) 
criteria (See Appendix A).  SIGN provided the audit tools necessary to distinguish 
reputable data, identify proficient guidelines for changes in practice, raise the standards 
of clinical care, and deliver improved patient outcomes (SIGN, 2013).   
2.2 Analysis 
 Current research has been analyzed to identify common symptoms, multi-
symptom prevalence, medications, routes of administration, education, and 
implementation of comfort care kits in hospice patients.  Analysis of literature has been a 
significant process utilized to support changes in current practice, policies, and 
guidelines. 
2.3 Symptoms   
Kehl and Kowalkowski (2012) conducted a systematic review to identify the most 
prominent signs and symptoms of imminent death that occur in an individual’s last two 
weeks of life.  These researchers utilized twelve peer-reviewed articles, representing a 
total of N=2416 patients located in various home-based settings (Kehl and Kowalkowski, 
2012).  They identified 43 unique symptoms and calculated the prevalence of symptoms 
within the population.  Kehl and Kowalkowski (2012) improved the validity and reduced 
the risk of bias through excluding studies that utilized retrospective recall in the 
collection of data on signs and symptoms.  The individual reviewers managed the articles 





Observational studies in Epidemiology (STROBE) to filter and eliminate articles that did 
not meet their criteria (Kehl and Kowalkowski, 2012).  The information collected from 
each article included the following: sample size; setting; study design; methods of data 
collection; diagnoses of study participants; assessment period (interval of time before 
death); number of symptoms evaluated; prevalence for each symptom; and overall studies 
results and/or outcomes (Kehl and Kowalkowski, 2012).   
Out of the 12 studies utilized, they were divided into “restricted” and 
“unrestricted.”  The authors considered studies where investigators identified specific 
signs or symptoms prior to the examination as “restricted” and others as “unrestricted” 
(Kehl and Kowalkowski, 2012).  The overall data on the prevalence of signs and 
symptoms were weighted and unweighted prevalence calculations (Kehl and 
Kowalkowski, 2012).  Weighted prevalence calculations were the mean for each sign and 
symptom across the studies (Kehl and Kowalkowski, 2012).  Unweighted prevalence 
calculated the average percentage for each sign and symptoms across studies (Kehl and 
Kowalkowski, 2012).  Weighted prevalence provides a more reliable representation due 
to the emphasis of results from studies with large sample sizes (Kehl and Kowalkowski, 
2012).  The researchers conducted a T-test using software SPSS 19.0 to determine the 
prevalence of symptoms amongst restricted and unrestricted studies (Kehl and 
Kowalkowski, 2012).   
The studies represented data from various countries including the United States, 
Japan, Canada, Spain, and Hong Kong (Kehl and Kowalkowski, 2012).  The settings 
included inpatient medical centers, palliative care units, long-term care units, outpatient 





and symptoms were identified throughout the analysis of all 12 studies (Kehl and 
Kowalkowski, 2012).  There was a wide variation in the prevalence of symptoms that 
ranged from 8.6% to 55.7% (Kehl and Kowalkowski, 2012).  Kehl and Kowalkowski 
(2012) identified the following as the most commonly reported symptoms: dyspnea 
(62.1% w, 56.1% u); weakness (54.4% w, 23.9% u); respiratory secretions (53.3% w, 
51.4% u); and pain (47.2% w, 52.8% u).  According to Kehl and Kowalkowski, (2012), 
the prevalence of the symptom dyspnea had a higher prevalence than pain in both 
weighted and unweighted calculations.  Respiratory secretions had a higher prevalence 
than pain in weighted prevalence calculations; however, it had lower prevalence in 
unweighted calculations (Kehl and Kowalkowski, 2012).  A limitation to this systematic 
review was the wide range of prevalence of signs and symptoms, variations in sample 
sizes, and different methods utilized to collect data amongst the various studies.  Another 
limitation to the study is the consistency with accurate patient assessment and 
documentation of a sign or symptom.  Also, documentation as a patient’s death 
approaches may be less complete due to the abrupt changes in patient status.  Kehl and 
Kowalkowski (2012) were rated a 1+ based on their level of quality through application 
of the Scottish Intercollegiate Guidelines Network (SIGN) criteria (See Appendix A).    
Bishop and colleagues (2009) identified a gap in knowledge regarding their 
policies on the administration of comfort medications and the use of hospice’s medication 
kits in homes to manage uncontrolled symptoms.  According to Bishop et al. (2009), 
“…there is little data to guide practice of managing symptomatic emergencies in the 
home” (p.37).  Medicare now requires hospice agencies to participate in the Medicare 





within our healthcare systems (Bishop et al., 2009).  In April 2005 through July 2005, 
Bishop and colleagues (2009) conducted a retrospective research survey analyzing 22 
hospice organizations across New Hampshire.  The survey was administered by phone 
interview, conducted by two Nurse Practitioners associated with the Dartmouth 
Hitchcock Medical Center, Palliative Care Specialty (Bishop et al., 2009).  The survey 
included questions regarding the following: the duration of time prior to ordering a 
hospice patient a medication kit and the availability of receiving the kit, “characteristics 
of prescribers, pharmacies, kit contents, costs, frequency of use, and perceived impact of 
kits” (Bishop et al., 2009).  Additionally, Bishop and colleagues’ (2009) survey included 
the following questions: “obstacles to obtaining kits; how often medications within kits 
are used, and the impact of their use” (p.38).  Descriptive statistics measurements were 
generated utilizing the program Stata, version 8.2. (Bishop et al., 2009).  Bishop et al. 
(2009) defined symptoms that cause negative clinical outcome or require emergency 
transport to a local hospital.  The symptoms include the following: pain, dyspnea, 
nausea/vomiting, seizures, acute anxiety, agitation/delirium, noisy secretions, and fever 
(Bishop et al., 2009).  Of the 22 hospice organizations, 59% of agencies had average 
daily census (ADC) less than 20 and 41% had ADC greater than 20 patients (Bishop et 
al., 2009).   
All participating hospice agencies reported they dispensed medication kits to 
relieve uncontrolled symptoms (Bishop et al., 2009).  The agencies named the kit in 
various terms: 50% used “emergency” in the kit’s title, 36% “symptom relief,” “relief 
kits,” and 14% used the title “comfort” (Bishop et al., 2009).  The providers prescribing 





primary care physician or hospice medical director (Bishop et al., 2009).  According to 
Bishop et al. (2009), 86% of the hospice agencies utilized a written protocol for 
administration of the kit and 27% had a protocol for specific negative situations such as 
cardiac problems.  The results regarding access to pharmacy concluded that 90% had 
twenty-four hour pharmacy access, 84% had access to a pharmacy that compounded 
medications, and 68% used community pharmacies (Bishop et al., 2009).  Fifty-two 
percent dispensed on admission and 33% within three days after the patient’s admission 
to hospice (Bishop et al., 2009).  Bishop et al. (2009) reported one hospice ordered the kit 
once a patient was unable to swallow and 76% of hospice reported that kits are ordered 
routinely for patients.  Sixteen agencies reported cost for kits: 12 reported cost to $50 or 
less and four reported a cost of greater than $50 (Bishop et al., 2009).  Frequency for 
ordering: 55% dispensed 1–10 kits in one month interval, 45% dispensed 10 or more kits 
per month, and those hospice’s with higher ADC dispensed more kits per month.  Of the 
dispensed kits: 82% reported kits were used in more than 50% of the cases (Bishop et al., 
2009).   
Hospice agencies must be prepared for symptomatic crisis at all times; otherwise, 
the families are forced to seek treatment for symptoms at an emergency room or acute 
care setting.  Eighty-five percent reported that kits helped avoid emergency room visits 
and 10% reported that it occasionally prevented unnecessary ER visits (Bishop et al., 
2009).  The hospice agencies utilized various medications in their kits (Bishop et al., 
2009).  All agencies’ kits contained medications to treat pain, agitation, and dyspnea; 
81% for nausea and vomiting and 76% for seizures (Bishop et al., 2009).  Routes of 





routes for consumption (Bishop et al., 2009).  The overall purpose is to prevent 
symptomatic crisis and improve the delivery of hospice care.  Hospice patients that reside 
in rural geographical areas can be negatively affected by the following: the length of time 
it takes for the appropriate hospice provider to arrive, assessment of symptomatic crisis, 
and access to pharmacy to obtain medications (Bishop et al., 2009).  Limitations to this 
research included: geographical bias due to the researchers conducting the survey in a 
single state, New Hampshire; sampling bias due to the small sample population utilized 
and selection of participants were not randomized; and reporting bias because the tool 
used to facilitate response was a survey and was a general impression of a single 
representative within a hospice agency that responded.  The survey was brief and did not 
ask about doses of prescribed medications or the quantities of medications dispensed.  
Bishop et al. (2009) reported significant variability in the types of medications, route of 
administration, and dosages between the hospice agencies.  Consistency in hospice 
agencies’ symptom relief kits contents and protocol are essential components in the 
delivery of quality care during the end-of-life transition.  Bishop and colleagues (2009) 
were rated a three based on their level of quality through application of the Scottish 
Intercollegiate Guidelines Network (SIGN) criteria (See Appendix A).      
Wowchuk, and colleagues (2009) conducted a simple descriptive study that 
addressed comfort and symptom crisis management in patients anticipated to die within 
two weeks in a nonmedical setting.  Wowchuk and colleagues (2009) illustrated that 
primary causes for unplanned admissions to hospitals during the last weeks of life 
included poor symptom control and/or caregiver role strain.  According to Wowchuk et 





become difficult to treat at home, due to changes in patient medication requirements or 
route of delivery that were not adequately anticipated and planned for” (p.798).  
Avoiding unplanned admissions into the hospital in hospice patients during the terminal 
phase includes access to anticipated medications for common symptoms that occur 
during the end-of-life transition and increased caregiver education regarding 
administration of comfort medications (Wowchuck et al., 2009).   
Winnipeg Regional Palliative Care Program established and piloted palliative 
medication kits (PMK) to manage symptomatic crisis. They included a variety of 
medications in the event more than one unanticipated symptom occurred and increased 
patients’ level of comfort during the end-of-life transition (Wowchuk et al., 2009).  
Wowchuk and colleagues (2009) stated that the PMKs included the following 
medications: morphine 50 mg/mL liquid for pain and/or dyspnea; hydromorphone 
10mg/mL injectable preparation for pain and/or dyspnea; methotrimeprazine 25mg/mL 
for sedative, anti-nauseant, dyspnea, and/or pain; lorazepam 1 mg sublingual to address 
anxiolytic, sedative, and/or anticonvulsants; and scopolamine transdermal gel 
0.25mg/0.1mL to address oral or respiratory secretions and/or nausea.  Wowchuk and 
colleagues’ (2009) pilot testing was approved by Winnipeg Regional Health Authority 
Palliative Care Program and partnered with a local pharmacy to obtain data from 2002 to 
2007.  The program placed PMKs in patients’ homes anticipated to die within two weeks 
and provided only a 24 hour supply of each medication (Wowchuk et al., 2009).  
According to Wowchuk and colleagues (2009), nurses followed guidelines to obtain, 





opened a PMK.  The palliative care program then submitted and analyzed this data 
(Wowchuk et al., 2009).   
Wowchuk and colleagues (2009) reported the following: 293 kits were dispensed 
and accessed; 43.7% of the population were women; overall average age was 70.3 years 
old; and mean survival for time the kit was opened until patient died was 4.54 days.  
Wowchuk et al. (2009) identified out of the 293 kits ordered for patients, 258 (88%) died 
at home, 28 (10%) in a palliative care unit, and two (1%) in an acute care environment.  
Wowchuck and colleagues (2009) reported the most prominent symptoms were pain 
(24%), retained secretions (23%), and agitation/delirium (21%) that included anxiety or 
confusion, dyspnea (14%), and nausea (4%).  The following medications had the highest 
frequency of utilization: methotrimeprazine (29%), scopolamine (28%), and dilaudid 
(20%) (Wowchuk et al., 2009).  Palliative care programs strive to facilitate appropriate 
methods with the provision of care delivered to actively dying patients at home.  These 
programs strive to avoid unnecessary emergency department encounters or unintended 
admissions to an acute care facility for patients that wish to receive palliative care in their 
own home (Wowchuk et al., 2009).  According to Wowchuk et al. (2009), frequently 
poor symptom control is the leading cause for an unplanned hospitalization within this 
patient population and PMKs were initially developed to extend the length of time 
patients can be cared for in their home.  Doyle’s assertion is that palliative care must plan 
for the future and order PMKs to prevent patient suffering from anticipated symptoms 
that occur during the end-of-life transition (Wowchuk et al., 2009).  Limitations include 
sampling bias with small sample size and nonrandomized sample size.  Reporting bias is 





median time interval of death was four days; therefore, retrieval of information may be 
difficult (Wowchuk et al., 2009).  Wowchuk and colleagues (2009) were rated a three 
based on their level of quality through application of the Scottish Intercollegiate 
Guidelines Network (SIGN) criteria (See Appendix A).      
Sera and colleagues (2014) conducted a Retrospective Cross-sectional Study to 
analyze commonly prescribed medications utilized within the hospice population.  
According to Sera and colleagues (2014), studies on the types of medications prescribed 
to patients receiving palliative care have shown that chronic conditions medication intake 
decreases whereas symptom management medication intake increases.  Sera and 
colleagues (2014) utilized data provided by a national hospice organization, Seasons 
Hospice & Palliative Care, located in 11 states.  Sera et al. (2014) study used patient 
electronic medical records (EMR) to gather the following data: clinical database of 
patient demographic and medication.  Patients included in the study were admitted to 
hospice on or after January 1, 2010, if they died in hospice on or before December 31, 
2010 (Sera et al., 2014).  The EMR provided the following information: drug name, 
dosage, formulation, strength, pharmacological class, and compounded formulations 
(Sera et al., 2014).  Sera and colleagues (2014) gathered the following demographic 
variables: age, sex, race, and state of residence.  They also evaluated the patients’ 
admitting diagnosis, location of care, and length of stay.  They utilized Microsoft Excel 
to run statistical analysis on all variables.  Sera and colleagues (2014) included (N=4252) 
hospice patients in this study located in 11 states.   
Sera et al. (2014) illustrated essential patient demographics as the following: 





Caucasian.  Sera and colleagues (2014) identified the most common primary admitting 
diagnosis was cancer at 34.6%,  the most common setting for hospice was reported at 
home 29.2%, and the average length of stay was 22.2 days (median eight days, range 1–
353 days).  Sera et al. (2014) reported out of the 100 most commonly prescribed 
medications in hospice population, the six most common drugs included in symptom 
management medication kits included the following: acetaminophen 85.8%, morphine 
84.4%, haloperidol 49%, lorazepam 84.5%, prochlorperazine 47.3%, and atropine 62.5%.  
Out of all drug classes, the most prescribed medications were reported for symptom 
management use (Sera et al., 2014).  Sera et al. (2014) identified that 60% of hospice 
patients were prescribed the following during admission: opioid and nonopioid 
analgesics, anxiolytics, anticholinergics, and antipsychotics.  According to Sera et al. 
(2014), hospice patients with cancer were commonly prescribed opiods, antipsychotic 
agents, corticosteroids, and antiemetic medications.  Hospice patients with dementia were 
commonly prescribed nonopioid analgesics, vitamins or supplements, and antiplatelet 
medications (Sera et al., 2014).  The majority of hospice patients with lung disease were 
prescribed bronchodilators (Sera et al., 2014).  Overall, the prescription of opioid 
analgesic medications showed a statistical significance with P value = 0.01 among the 
hospice patients admitted with cancer, dementia, and lung disease.  Sera et al. (2014) 
identified the importance for additional research concerning particular end stage diseases 
and specific medications that provide positive patient outcomes with symptom 
management.  The sample bias was the use of only one national hospice organization.  
This study identified the reporting bias by data regarding medication use that was not 





through application of the Scottish Intercollegiate Guidelines Network (SIGN) criteria 
(See Appendix A).      
Comfort and being free of all symptoms are the main wishes of a patient during 
their final days (Klinkenberg et al., 2004).  Klinkenberg and colleagues (2004) reported 
that end-of-life patients are a vulnerable population and research cannot be generalization 
to the entire terminal population.  They believed that conducting “after death interviews” 
with relatives of the loved one approaches the perception of the experience differently 
(Klinkenberg et al., 2004).  Klinkenberg and colleagues (2004) conducted a retrospective 
research study.  The sample (N=270) included the relatives of decedents’ (aged 59–91) 
evaluation of symptom control and outcomes as reported by relatives after the death 
(Klinkenberg et al., 2004).  Klinkenberg et al., (2004) analyzed the presence of symptom 
burden, the associations (overall and symptom specific), chronic diseases, and cognitive 
functioning.  The study randomly retrieved the sample of 3,107 subjects from older 
participants aged 55 to 85 years old from the Longitudinal Aging Study Amsterdam 
(LASA).  In September 1992 to 1993, they completed a baseline interview and in 
September 1995 to 1996, they conducted a follow-up interview.  Only 270 proxy 
members participated.  They consisted of spouses or children of the deceased hospice 
patient (Klinkenberg et al., 2004).  Twenty-six months was the mean time between death 
and the interview with the relative.  The interval of time ranged from four months to 
almost four years (Klinkenberg et al., 2004).  The following characteristic of participants 
was recorded: sex, age at death, type of residence at three months before death, and place 
of death (Klinkenberg et al., 2004).  According to Klinkenberg and colleagues (2004) 





week of life include the following: fatigue, pain, shortness of breath, depression, anxiety, 
confusion, and nausea/or vomiting.  The interview consisted of questions regarding the 
deceased relative’s cognitive decline, presence of chronic diseases, consciousness during 
the last week of life, and ability to communicate and make decisions (Klinkenberg et al., 
2004).  The sample utilized consisted of 167 men (62%) and 103 women (38%) with a 
mean age of 80 years old (Klinkenberg et al., 2004).  According to Klinkenberg and 
colleagues (2014), almost half of the sample had two or more chronic diseases while 10% 
reported none.  Thirty-six percent reported cognitive decline over the last three months of 
life and 34% were unable to make decisions in the last weeks of life.  Out of the 34% 
unable to make decisions, 15% were not capable of communicating, while 4% were 
nonresponsive throughout the last weeks of life (Klinkenberg et al., 2004).   
Klinkenberg and colleagues illustrated with this population the prevalence of 
symptoms during the end-of-life transition are the following: fatigue (83%), shortness of 
breath (50%), pain (48%), confusion (36%), anxiety (31%), depression (28%), and 
nausea and/or vomiting (25%) (Klinkenberg et al., 2004).  Klinkenberg et al. (2004) 
reported that (75%) of the population had two or more symptoms and (9%) reported no 
symptoms during their last week of life.  Klinkenberg and colleagues (2004) identified 
that patients with severe cognitive decline reported a higher symptom level than patients 
with no or low cognitive decline.  Patients with terminal cognitive decline demonstrated 
higher score on all symptoms with the exception of pain and shortness of breath during 
the end-of-life transition (Klinkenberg et al., 2004).  Through their analysis of the 
relationship between chronic disease and symptom burden, the following three diseases 





(P<0.001), and cancer (P<0.001).  COPD was associated with an increased chance the 
patient suffered from shortness of breath (OR = 12.7; 95% CI: 5.4-30) and cancer patients 
have an increased incidence of suffering from pain (OR = 3.9; 95% CI: 1.7-16.7).  
According to Klinkenberg et al. (2004), cognitive decline is problematic to symptom 
management due to a patient’s inability to communicate; therefore, it is essential to 
monitor these patients’ non-verbal cues.   
According to Klinkenberg and colleagues (2004), results revealed it was not 
uncommon that patients from the Netherlands suffered from symptoms during the end-of-
life transition.  Limitations include geographical bias due to the study conducting the 
survey in the Netherlands.  Reporting bias is applicable to this study because it collected 
data regarding the relatives and caregivers’ perception of the deceased patients’ 
distressful symptoms during the end-of-life transition.  Additionally, another limitation 
was the variation in the length of time between the patient death and interview of 
caregiver.  According to Klinkenberg et al. (2004), the participants selected died between 
1995 and 1998; therefore, accuracy in recall of patient’s symptoms could be problematic.  
Klinkenberg and colleagues (2004) were rated a 2 + based on their level of quality 
through application of the Scottish Intercollegiate Guidelines Network (SIGN) criteria 
(See Appendix A).      
Common symptoms found throughout the hospice patient population have been 
pain, dyspnea, nausea/vomiting, seizures, agitation, acute anxiety, and delirium.  Kehl 
and Kowalkowski (2012) found in multiple studies that the most commonly reported 
symptoms during the last two weeks of life were dyspnea, weakness, respiratory 





90% of seriously ill patients and healthcare providers valued being free of pain, anxiety, 
and shortness of breath in the last days of life as most important.  According to Wowchuk 
et al. (2009) the study demonstrated that the most prominent symptoms addressed in 
hospice patients were pain, nausea, vomiting, shortness of breath, agitation, confusion, 
retained respiratory secretions, and weakness.  In comparison Sera and colleagues (2014) 
reported that the most prominent symptoms encountered in hospice patients at end-of-life 
were pain, dyspnea, nausea, delirium, anxiety, and depression.  Klinkenberg et al. (2004) 
found that the seven most prominent symptoms identified as burdensome during the last 
two weeks of life included fatigue, pain, shortness of breath (dyspnea), anxiety, nausea, 
confusion, and depression.  Out of their sample, only 9% of the population had been 
symptom free during the last week of their life (Klinkenberg et al., 2004).   
Bishop and colleagues (2009) reported symptomatic crises were highest in 
prevalence among hospice patients as compared to most non-end-of-life populations.  
Managing these symptoms has been critical to the end-of-life transition, as the majority 
of hospice patients reported the desire to remain at home throughout the end of their lives 
(Bishop et al., 2009).  Symptomatic crises involved the following conglomerate of 
variables: understanding end-of-life symptoms; providing education to patients and 
caregivers to identify which medications to utilize in order to control the present 
symptoms; understanding the medical management in hospice patients who were rapidly 







2.4 Dyspnea.   
Conill and colleagues (1997) conducted a descriptive study to assess the 
frequency of symptoms during a patient’s last days of life and utilized this data as a 
comparison of the patient’s symptoms reported at their first evaluation.  The study 
included consecutive patients (N=176) whom passed away at their home, in a hospice 
regional social health support area, or in a hospital setting (Conill et al., 1997).  The 
participants were involved during a one-year timeframe (January through December 
1994) and given a questionnaire to assess the prevalence of symptoms at first evaluation 
and then during the last seven days of life (Conill et al., 1997).  End-of-life patient 
population with advanced diseases belonged to various settings including the following: 
Department of Radiation Oncology, Hospital Clinic, Regional Area of Social Health 
Support, Home Care Teams, and Hospice (Conill et al., 1997). The mean age of patients 
was 67.7 years of age that included men (N=121) and women (N=55) (Conill et al., 
1997).  The mean time interval between the first and second assessment was 6.5 weeks 
(Conill et al., 1997).  A total of 56.8% of patients’ second assessment interview were 
conducted during their last 48 hours of life (Conill et al., 1997).  The top three reported 
symptoms by participants in both assessments included asthenia, anorexia, and dry mouth 
(Conill et al., 1997).  Conill and colleagues (1997) identified that the prevalence of pain 
was reported higher at the first assessment (52.3%) and reported lower (30.1%) during 
the second assessment.  Also, 64.2 % of the patients involved in the study passed away in 
their home (Conill et al., 1997).  Limitations to this study include the patient’s differential 
life-limiting diseases.  There is reporting bias because patients experience various 





indicate if the participants were a randomized sample.  Conill and colleagues (1997) were 
rated a 3 based on their level of quality through application of the Scottish Intercollegiate 
Guidelines Network (SIGN) criteria (See Appendix A).      
Tranmer, Heyland, Dudegeon, Groll, Squires-Grahman, and Coulson (2003) 
participated in a descriptive study to compare symptom experience between hospitalized 
cancer and non-cancer patients near the end-of-life.  Tranmer and colleagues (2003) 
utilized the Memorial Symptom Assessment Scale (MSAS) to compare symptom 
experience and to determine if this tool was a valuable measurement for symptom 
distress in noncancer patients and Piper Fatigue Scale (PFS), a measurement tool of the 
symptom fatigue.  Tranmer et al. (2003) explained common symptoms experienced at the 
end-of-life transition are fatigue, anxiety, and/or pain, which are associated with a 
decreased level of comfort in this population.  The (MSAS) was developed to evaluate 
symptom prevalence, frequency, severity, and distress (Tranmer et al., 2003).  Tramner 
and colleagues (2003) conducted an exploratory analysis at a hospital in Ontario, Canada, 
during June 1999 to November 2000.  Patients were screened on admission to the 
university-affiliated hospital’s medical or surgical floors for prospective eligibility 
(Tramner et al., 2003).   
Patients 18 years or older with one of the following diseases and a prognosis of 
50% at six months were included in the analysis: Chronic Obstructive Pulmonary Disease 
(COPD), Congestive Heart Failure (CHF), Cirrhosis, and Cancer.  Researchers conducted 
face-to-face interviews with consenting patients utilizing a questionnaire package that 
contained both the MSAS and the Piper Fatigue Scale (PFS) (Tranmer et al., 2003).  The 





the tool used to compute statistical analysis of data was evaluated with the utilization of 
SAS Version 8.2 (Tranmer et al., 2003).  Tranmer et al., (2003) illustrated only one 
statistical significance with the demographics amongst both groups: non-cancer patients 
were older (average 79 years old), versus cancer patients (64 years old).  Additionally, 
non-cancer patients had a higher prevalence of admission to inpatient hospital ICU or 
step down units in comparison to cancer patients.  They identified that cancer patients 
(41%) were most likely to receive palliative care over non-cancer patients (6%).  Tranmer 
et al. (2003) demonstrated that the six-month mortality rate was significantly higher in 
cancer patients (51%).  Patients in the cancer group reported a significantly higher 
prevalence (P<0.01) of the following symptoms in comparison to non-cancer patients: 
pain (78% vs. 49%), nausea (61% vs. 28%), unpleasant taste (50% vs. 19%), constipation 
(48% vs. 38%), and vomiting (41% vs. 10%).  The non-cancer group demonstrated the 
following significant results with their experience of prominent symptoms: shortness of 
breath (86% to 38%) and cough (72% to 52%) over the cancer patients’ prevalence 
(Tranmer et al., 2003).  The study identified no prevalence of psychological symptoms as 
statistically significant between the two groups (Tranmer et al., 2003).   
Tranmer and colleagues (2003) determined through the analysis of symptom 
characteristics that non-cancer patients revealed greater frequency of weight loss (64% 
vs. 32%), increased distress associated with dizziness (35% vs. 5%), and coughing (48% 
vs. 21%).  The symptom score associated with coughing acknowledged a significance, 
cancer patients score (1.74 vs. 2.29) (P<0.05).  The prevalence of symptoms was high in 
both non-cancer and cancer patients, the average number of symptoms experienced was 





The cancer group illustrated a significantly higher prevalence of the symptoms pain, 
nausea, unpleasant taste, vomiting, and constipation (Tranmer et al., 2003).  The non-
cancer group reported a higher prevalence of shortness of breath and cough (Tranmer et 
al., 2003).  Tranmer and colleagues (2003) identified no significant difference in 
prevalence of psychological symptoms between the two groups.  Tranmer and colleagues 
(2003) illustrated the significance to research the distinct physical symptoms associated 
with specific illnesses.  This supports the implementation of comfort care kits into end-
of-life care patients’ environments to alleviate various symptoms during crisis until 
further assessment is accomplished.  Severity scores were higher in both groups than 
frequency and distress scores (Tranmer et al., 2003).  The following highest symptom 
results of both groups included the following: pain (2.80), lack of energy (2.76), 
shortness of breath (2.75), difficulty sleeping (2.61), dry mouth (2.57), and feeling 
worried (2.56).  The prevalence was found to be different; however, the distress from 
pain was found to be similar between the two groups (Tranmer et al., 2003).  When 
cancer patients experienced shortness of breath the distress was statistically significant to 
experiences report by COPD and CHF patients.  The illustrated that both cancer and non-
cancer patients experience multiple symptoms frequently during the end-of-life transition 
(Tramner et al., 2003).  They identified MSAS was an adequate tool in the utilization of 
calculating symptom prevalence and other relationships in non-cancer patients.  One 
limitation to this study was reporting bias, Tranmer and colleagues (2003) explained 
patients may not perceive coughing, shortness of breath, or feeling worried as a symptom.  
Another reporting limitation was the patients symptom experienced was measured only 





(2003) were rated a 2+ based on their level of quality through application of the Scottish 
Intercollegiate Guidelines Network (SIGN) criteria (See Appendix A).      
A study by Wowchuk and colleagues (2009) reported that retained respiratory 
secretions and subsequent dyspnea were the most common causes of distress experienced 
during the terminal phase by this vulnerable population.  These findings paralleled a 
study by Kehl and Kowalkowski (2012) that reported out of 43 symptoms experienced in 
the last two weeks of life, those identified with the highest prevalence had been dyspnea 
56.7% over pain 52.4%.  They also found in multiple studies that the prevalence of 
dyspnea (62.1% weighted, 56.1% unweighted) was more prominent than pain (47.2% 
weighted, 52.8% unweighted) (Kehl & Kowalkowski, 2012).  According to Conill et al. 
(1997) dyspnea is a distressful symptom during the end-of-life transition that often goes 
unreported by patients and unnoticed by healthcare professionals.  Tranmer et al. (2003) 
compared symptoms of seriously ill cancer patients and noncancer patients during their 
end-of-life transition.  Tranmer and colleagues (2003) found that noncancer patients 
reported a higher prevalence of dyspnea (86%) versus patients with cancer (38%).  
During Klinkenberg and colleagues’ (2004) study on prevalence of symptoms and 
symptom burden during the last week of life, dyspnea (50%) and pain (48%) was present 
in over half the population sample.     
2.5 Increased Respiratory Secretions. 
Kintzel and colleagues (2009) conducted a literature review to identify the 
effectiveness of using anticholinergic medications to reduce the symptom noisy 





frequency for terminal patients suffering from noisy secretions is 31% to 92%.  When a 
patient is actively dying (generally within 24 hours prior to their death) noisy secretions 
generally become a prominent symptom (Kintzel et al., 2009).  Kintzel and colleagues 
(2009) listed the following as standard measures to alleviate noisy secretions include: 
position patient semi-prone, decrease or withhold parental hydration, family and/or 
caregiver education, gentle suctioning, and administration of anti-secretory medications.  
Medications used to assist with symptomatic relief of noisy secretions include atropine, 
glycopyrrolate, scopolamine, and scopolamine derivatives (Kintzel et al., 2009).  These 
medications are unable to relieve prior retained secretions; however, the reduced the 
production of bronchial secretions (Kintzel et al., 2009).  In the literature review, Kintzel 
and colleagues conducted the “anticholinergic medication regimen underwent 
interdisciplinary review by institutional pharmacist, physicians, nurse educators, and 
hospice nurses before its inclusion in comfort care order set” (p.459).  Kintzel et al. 
(2009) analyzed reports that utilized clinical data for symptom management of noisy 
secretions in hospice patients and management and drooling in non-hospice patients.  
  Kintzel and colleagues (2009) utilized six studies to analyze evidence for use of 
anticholinergic medication in hospice patients.  One study used scopolamine 
hydrobromide, scopolamine butylbromide, and glycopyrrolate effectiveness for relieving 
noisy secretion (Kintzel et al., 2009).  The effectiveness of treatment was evaluated on a 
scale of mild, moderate, or severe by the nurse that administered the anticholinergic 30 
minutes prior (Kintzel et al., 2009).  Additionally, the intensity of distress displayed by 
relatives was measured as not at all, a little, quite a bit, and very much (Kintzel et al., 





butylbromide and glycopyrate regimens show increased improvement for hospice 
patients’ outcomes with management of retained secretions. 
Kintzel and colleagues (2009) demonstrated that two additional studies assessed 
the effectiveness after the institutional changes from scopolamine to glycopyrrolate.  
Researchers administered both medications first by initial bolus following continuous 
infusion.  Data was collected by nurses’ rating of patients utilizing a noise score.  The 
noise scale was rated at four separate events: at the time of study entry, 30 minutes after 
the first dose, 30 minutes following a repeated dose, an then every four hours until the 
patient expired (Kintzel et al., 2009).  According to Kintzel and colleagues (2009), the 
median age was 71 years old (range 33–92 years old).  Scores after the initial dose of 
anticholinergic medication was better in scopolamine-treated group (56%) in comparison 
to the glycopyrrolate-treated patients (39%) (P value = 0.002).  This is statistically 
significant.  A repeated dose of anticholinergic medication was administered to 33% (36–
108) of patients treated with scopolamine and 50 % of (31–62) of patients treated with 
glycopyrrolate (p=0.05).  Kintzel et al. (2009) identified glycopyrrolate and scopolamine 
had equal effectiveness.  One study utilized data from institutionalized hospice patients 
suffering from increased respiratory secretions and receiving an anticholinergic (Kintzel 
et al., 2009).  Actively dying patients were assessed every four hours for the presences of 
the following symptoms: respiratory secretions, agitation, and pain (Kintzel et al., 2009).  
Patients treated with glycopyrrolate had a more positive response (p< 0.01) over those 
administered scopolamine (Kintzel et al., 2009).  Patients administered glycopyrrolate 
had a longer median of time between the onset of symptoms from respiratory secretions 





Additionally, study authors analyzed a report on the usage of parental 
scopolamine to manage noisy secretions in hospice patients (Kintzel et al., 2009).  One 
studied reported an increase in agitation witnessed in patients treated with scopolamine 
versus receiving glycopyrrolate; however, the study overall identified no significance in 
the difference between either medication to relief noisy secretions.  Kintzel et al. (2009) 
illustrated the difficulty in obtaining data from this population due to potential 
unconscious patients, decreased assessment of vital signs, and/or, laboratory monitoring 
during the final days preceding hospice patient’s death.  The studies of the use of 
anticholinergics medications in nonhospice patients to manage sialorrhea and excess 
drooling could potentially benefit noisy secretions in hospice population (Kintzel et al., 
2009).  The anticholinergic medications used in the non-hospice population are mainly 
focusing on patients with neurologic disorders, disabilities, and medication induced 
salivation (Kintzel et al., 2009).  In the pediatric population with cerebral palsy and/or 
other neurological development disorders, the anticholinergic oral glycopyrrolate 
improved salvation and drooling (Kintzel et al., 2009).  Utilization of transdermal 
scopolamine patches were essential component of the medication regimen to alleviate the 
symptoms of hyper-salivation or noisy secretions in 109 patients with various medical 
conditions (Kintzel et al., 2009).   
Kintzel and colleagues (2009) reported reduced salivation in patients with 
advanced peritoneal cancer and atropine drops 1%, twice a day to reduce severity of the 
symptom drooling in Parkinson patients.  Reason for additional testing of sublingual 
ipratropium as alterative to sublingual atropine ophthalmic drops included the following 





administering atropine drops (Kintzel et al., 2009).  Impending signs of death include 
noisy secretions, confusion, agitation, pain, dyspnea, and tachypnea and can cause 
distress in hospice patients, caregivers, family members, and staff (Kintzel et al., 2009).  
Kintzel et al. (2009) explained that subcutaneous scopolamine hydrobromide and 
subcutaneous scopolamine butylbromide have not been commercially licensed for use in 
the United States.  According to Kintzel and colleagues (2009) sublingual administration 
of ipratropium solution is an alternative to glycopyrrolate and atropine; however, no 
reports in hospice patients were identified.  They illustrated the significance of 
medication regimens for palliative care should be developed from clinical evidence of 
efficacy, safety, cost, product availability, and administration expediency (Kintzel et al., 
2009).  Reporting bias was present due to the noise score being assessed from nurse’s 
perception.  Kintzel and colleagues (2009) were rated a 4 based on their level of quality 
through application of the Scottish Intercollegiate Guidelines Network (SIGN) criteria 
(See Appendix A).      
            A literature review that described treatment options for noisy secretions in 
hospice patients reported that the prevalence for the symptom of noisy respirations were 
present in terminal patients ranges from 31% to 92% (Kintzel et al., 2009).  When 
changes in a patient’s respirations occurred, such as the auscultation of noisy secretions 
without usage of a stethoscope, the hospice nurse usually reported the patient’s 
debilitating status to the healthcare provider.  Kehl and Kowalkowski (2012) reported out 
of 43 symptoms experienced in the last two weeks of life, those identified with the 
highest prevalence also included  respiratory secretions (54.1.%).  The weighted 





(47.2%) during the end-of-life transition (Kehl & Kowalkowski, 2012).  Noisy secretions 
have been associated with the characteristic of a patient actively dying (Kintzel et al., 
2009).   
2.6 Pain.   
Zerzan and colleagues (2010) analyzed various medications administered at end-
of-life hospice patients that alleviate distressful symptoms including pain.  In 2004–2006, 
Zerzan and colleagues (2010) utilized the University of Colorado’s Cancer Center and 16 
hospices to analyze the variable of medication usages.  They conducted a secondary 
analysis of randomized trial data, examining use of five medication classes: opiates, 
nonsteroidal anti-inflammatory drugs (NSAIDs), adjuvant pain medications (tricyclic and 
anti-seizure), stimulants, and antianxiety medications in 16 study sites nationwide. 
Zerzan and colleagues (2010) illustrate that hospice companies themselves can 
potentially drive the choice of medications to the most cost-effective pharmaceutical plan 
of care used to treat particular symptoms.  Zerzan and colleagues (2010) hypothesized 
that a hospice patient and their environment effects both the variation of medications 
used and their frequency of administration.  Descriptive statistics and frequency 
variations were generated for patient-level data and characteristics of the environment 
where the patient receives care (Zerzan et al., 2010).  Zerzan and colleagues (2010) used 
the following variables: age, gender, education, marital status, patient environment at 
home or facility, primary cancer type, location of bony spinal metastases, neuropathic 
pain, Karnosky Performance Status (KPS) scale, and the overall current mean of patients’ 
pain scores.   The study authors calculated the unadjusted and adjusted odds ratios to 





class use by site.  Adjusting for the following variables: age, education, marital status, 
patient environment at home or facility, primary cancer type, location of bony spinal 
metastases, neuropathic pain, Karnosky Performance Status (KPS) scale, baseline from 
the Brief Pain Inventory (BPI), lung cancer, breast cancer, and death. The variable gender 
was excluded from this particular analysis due to its strong correlation with breast cancer 
and women.  Researchers performed statistical analysis using software SAS Version 9.1 
(Zerzan et al., (2010).  This illustrated several components related to the various 
medication usages in 380 patients.  The average BPI score was 4.5 at the patient’s entry 
into study.  Patient’s average age was 64.7, the majority of the patients were male 39%, 
79% were at home, 25% had bony metastases, and 25% were experiencing neuropathic 
pain (Zerzan et al., 2010).  Also, 21% of patients were not taking any form of opiate in 
their medication regimen (Zerzan et al., 2010).   
Zerzan and colleagues (2010) identify “variation in medication use was not 
predicted by most patient characteristics or location of care (home versus facility).”  
Medication use varied between sites: “a range of 14%–83% of patients were on different 
types of opiates, 0%–40% on NSAIDS, 20%–69% on benzodiazepines, 0%–25% on 
adjuvant medications, and 0%–23% were on acetaminophen” during any duration of their 
data collection period (Zerzan et. al, 2010).  Also, Zerzan et al. (2010) described that the 
usage of all types of pain medications decreased with the patient’s age (odds ratio [OR] 
0.75 [0.63–0.90]).  Opiates were used less in the home environment 83.8% versus the 
facility 94.7%; however, the p-value was 0.02 identifying no statistical significance.  
Patients reporting neuropathic pain more likely received a NSAIDs and an additional pain 





sampling bias because patients enrolled in this study may not represent all patients and 
reporting bias because medications were self-reported.  Also, two sites used a formula 
plan of care established by a pharmacy manager and two other sites had no formula to 
guide medication usage (Zerzan et al., 2010).  The study’s strengths include the 
utilization of a large sample size (N= 380) and the inclusion of various geographical 
locations around the nation (Zerzan et al., 2010).  Zerzan and colleagues (2010) describe 
a purpose of the research is to produce information on how the variation in opiate use 
relates to a patient’s outcome to improve the end-of-life transition.  Zerzan and 
colleagues (2010) were rated a 2+ based on their level of quality through application of 
the Scottish Intercollegiate Guidelines Network (SIGN) criteria (See Appendix A).    
Maltoni, Miccinesi, Morino, Scarpi, Bulli, Martini, Canzani, Dall’Agata, Paci, 
and Amadori (2012) investigated the benefits of palliative sedation used for hospice 
patients experiencing refractory symptoms.  Maltoni and colleagues (2012) conducted an 
observational, prospective, cohort study in two Italian palliative care units with their 
focus on documentation of clinical practice of palliative sedation.  Refractory symptoms 
can be defined as symptoms that one experiences that are uncontrolled in an adequate 
amount of time despite the utilization of an aggressive usual treatment regimen.  The 
purpose of their research included the following: investigation of the clinical process, 
observation, and examination of patient’s survival time from the use of palliative 
sedation.  The study was conducted over a nine-month period from October 2009 to June 
2010 with a sample of (n=327) patients admitted to two separate Italian hospices with 11 
beds.  Maltoni and colleagues (2012) used descriptive statistical analyses and SAS to 





208) and Hospice B with 36.4% (n= 119).  The median age for hospice A was 66 years 
old and Hospice B was 77 years old (P value = 0.005).  Duration of hospice stays were 
the following: 13.5 days versus Hospice B 18.3 days (P<0.005).  The following were the 
death rates of the hospice patients: Hospice A = 57%, Hospice B = 89.9% (P<0.0001).  
Patients involved in the decision-making process regarding sedation were Hospice B 
(59.3%) significantly higher than patients in Hospice A (24.4%) with (P=0.007).  Overall, 
there was no effect on the survival time of patients with the utilization of palliative 
sedation.  Maltoni and colleagues (2012) monitored the following: date of entry, reason 
for admission into hospice, source of request, and date of death or discharge from the 
hospice.  The utilization of benzodiazepines was the focus of controlling refractory 
symptoms (Maltoni et al., 2012).  Average length of stay in both hospices was Hospice A 
= 13.5 days and Hospice B = 20.3 days (P=0.0001).  Therefore, Hospice B has a greater 
proportion of longer stays.  Overall, 31.9% of the 226 patients died in hospice with 25.2 
% belonging to Hospice B and 37.8% belonged to Hospice A.  The prevalence of 
refractory symptoms were delirium (61.1%), existential distress (37.5%), dyspnea 
(29.2%), and pain (20.8%) used as a reason to implement palliative sedation.  When PS 
was implemented, the prevalence of patients receiving morphine was 87.5%, receiving 
neuroleptics was 37.5%, and receiving benzodiazepine was 76.4%.  Morphine (87.5%) 
was the most widely utilized opioid.  Haloperidol was the neuroleptic of choice and 
Midazolam (95.8 %) following lorazepam.  Average overall survival calculated from 
admission to death in Hospice A was 18 days and in Hospice B was 10 days (P=0.205).  
However, mean survival time in both hospices between when sedated and non-sedated 





(n=154).  The death rate was higher among Hospice B (89.9%) versus Hospice A 
(52.7%).     
The Italian geographical setting of the hospices can be portrayed as a bias threat 
or limitation to this study.  Another limitation includes the proportion of existential 
distress and delirium in two hospices that can be attributed to clinicians’ difference in 
interpreting hospice patient’s symptoms. Utilizing case mixes can impact healthcare 
decision making due to cultural, professional, and background differences and changes in 
medical decision making.  One example of the case mix difference is Hospice A’s 
population was admitted proportionately more acute symptoms than that of Hospice B.  
In conclusion, palliative sedation is an appropriate clinical procedure in patients with 
advanced cancer; furthermore, well-monitored PS for refractory symptoms does not have 
a detrimental effect on survival.  Maltoni and colleagues (2012) were rated a 2+ based on 
their level of quality through application of the Scottish Intercollegiate Guidelines 
Network (SIGN) criteria (See Appendix A).      
Kutner, Bryant, Beaty, and Fairclough (2007) conducted a descriptive study to 
analyze the time course and characteristics of symptom distress and QOL in 
hospice/palliative care setting.  Kutner and colleagues (2007) identified the primary goal 
of palliative care was to alleviate distressful symptoms and enhance the patient’s quality 
of life.  Kutner et al. (2007) explained the significance in identifying the following in the 
end-of-life transition: most prevalent distressful symptom, change over time, factors that 
contribute to both symptom distress and decreased QOL.  Kutner and colleagues (2007) 
explored two hypothesis: first the difference in symptom incidence, prevalence, and 





Kutner et al.’s (2007) second hypothesis is that symptom distress correlates with a 
reduced QOL in hospice and palliative care populations.  The population Kutner and 
colleagues (2007) utilized in the study included patients (N=66), nurses (N=49), and 
caregivers (N=49) among 11 hospice palliative care organizations geographically located; 
10 from Colorado and one from Illinois.  Trained hospice staff members collected the 
data through patient interviews (Kutner et al., 2007).  Data collection was conducted at 
care enrollment, one-week and two-week enrollment, and for patients who survived two 
weeks, data was obtained monthly (Kutner et al., 2007).  The amount of data collected 
decreased over the two weeks in relationship to the patient dying.  Therefore, analysis for 
Kutner and colleagues (2007) date was collected through a total of 17 days following 
admission to the hospice/palliative care organization.  Kutner et al. (2007) utilized the 
following tools: the Memorial Symptom Assessment Scale (MSAS) to measure physical 
symptoms and Psychological Symptom subscale score (MSAS-PSYCH) to measure 
psychological symptoms.  The two open-ended questions focused on opinion of most 
distressful symptom and why.  Researchers used the MDQOL to measure the quality of 
life among advanced cancer patients.  They used the Karnofsky Scale to measure the 
patient’s functional status.  Kutner and colleagues (2007) collected the following 
variables from the patient population: sex, age, race/ethnicity, marital status, and the 
referral source, date of admission, diagnoses, and treatment setting.  The nurse 
participants provided the following data: years of hospice experience, amount of time 
spent with patient, patient environmental location and/or change of stay, and sources of 
information used with patients.  Caregivers provided the following information: age, sex, 





used to complete forms (Kutner et al., 2007).  Study authors analyzed data for statistical 
significance with Proc Mixed (Kutner et al., 2007).  Kutner et al. (2007) identified the 
following demographical data results: mean age was 72 years, most participants were 
non-Hispanic, white (95%), more participants were female (53%), 49% had a college or 
graduate degree, and 58% are married or in a committed relationship.  Kutner and 
colleagues (2007) identified symptoms measured by MSAS during days 0–17 with the 
most prevalence was lack of energy (92%), pain (82%), dry mouth (75%), and shortness 
of breath (73%).  However, the study identified pain as the most distressful symptom 
reported by both patients and their proxies (Kutner et al., 2007).  The MSAS and MQOL 
scale scores indicated pain contributed to increasing overall symptom distress.  Distress 
from the symptom pain decreased during the first week after admission and the MQOL 
tended to improve closer to death (Kutner et al, 2007).  Kutner and colleagues identified 
that mean distress from physical, non-pain symptoms have a significant association with 
increased pain.  Mean pain distress increased by 0.61 points with MSAS nonpain 
physical symptom distress score (Kutner et al., 2007).  A positive correlation was 
identified with QOL in cancer patients and increasing age (Kutner et al., 2007).  
However, psychological distress had a negative association with the QOL score.  Kutner 
et al. (2007) illustrated the increased prevalence of distressful symptoms was 
significantly associated with pain experience and psychological symptom distress was 
associated with decreased quality of life.  Kutner and colleagues (2007) illustrated 
“distress due to pain was associated with the presence of nonpain symptom distress” 
(p.234).  Kutner et al. (2007) identified the need to research studies of interventions 





Sampling biases in this study include a limitation with the study’s small sample 
size. The limitation is missing data, patient participation continued to decline in relation 
to patient’s death, and missed assessments were not recorded (Kutner et al., 2007).  
Another sampling bias is due to lack of racial/ethnic diversity; therefore, limiting the 
study’s findings to be generalized to other ethnicities.  Kutner and colleagues’ (2007) 
research supports the significance for an evidence base to guide symptom treatment 
interventions within this vulnerable hospice population.  Kutner and colleagues (2007) 
were rated a 2- based on their level of quality through application of the Scottish 
Intercollegiate Guidelines Network (SIGN) criteria (See Appendix A).      
Johnson and colleagues (2005) investigated the prevalence of symptoms for 
hospice patients and barriers and illustrated that the highest priority for these 
organizations is symptom management.  Johnson and colleagues (2005) conducted a 
descriptive analysis study that identified barriers to effective symptom management from 
a hospice nurse’s perspective.  The second goal of Johnson and colleagues’ (2005) 
research was to illustrate how symptoms vary among individual hospice patients.  The 
overall goal was to improve symptom management for terminally ill patients during the 
end-of-life transition (Johnson et al., 2005).  Participants in the study included hospice 
nurses currently practicing clinically in a hospice organization and affiliated with 
Population-based Palliative Care Research Network (PoPCRN).  The organization 
PoPCRN encompassed 128 hospice organizations geographically located in the United 
States and Canada (Johnson et al., 2005).  Researchers surveyed the clinical care nurses 
from participating hospice organizations between April and August 2002 (Johnson et al., 





review for symptom management in hospice care.  The symptom management model 
consisted of following five steps: symptom recognition, symptom assessment, care plan 
design, implementation, and reassessment (Johnson et al., 2005).  Johnson and colleagues 
utilized this model during the development of the surveys.  The survey encompassed four 
sections with an overall total of 25 questions.  Section one included demographic data; 
section two had nurses identify information resources (guidelines and/or protocols) used 
to guide plan of care; in section three nurses identified the five most prominent symptoms 
based on their experience; and section four allotted the nurses to identify barriers to 
effective symptom management (Johnson et al., 2005).  There were (N=867) clinically 
active hospice nurse participants from (N=67) hospices located in the U.S., permitted a 
total of six weeks to complete and return the surveys (Johnson et al., 2005).   
Johnson and colleagues (2005) utilized the SPSS (11.0 Version) statistical 
software for analyses and interpretation of collected data.  The demographic results were 
identified as the following: mean hospice experience (10.5 years); Registered Nurses 
(64%); Bachelor in Science of Nursing (26%); Licensed Practical Nurse (9%); Nurse 
Practitioner (1%); (80%) provided hospice care in the patients’ homes (Johnson et al., 
2005).  According to Johnson et al. (2005), out of 32 common symptoms the data 
revealed nurses reported the following symptoms the most difficult to manage: agitation 
(45%), pain (40%), dyspnea (34%), confusion (33%), and pressure ulcers (27%).  
Johnson and colleagues (2005) illustrated the most common barriers to effective 
symptom management were the following: 34% reported the inability for family 
caregivers to implement of maintain recommended treatments; 38% recommended 





other symptoms; and 33% accepted the symptom as a consequence of current treatment.  
According to Johnson and colleagues (2005), each of the top 15 symptoms illustrated 
statistical significant differences (P<0.0001) in their rankings of barriers associated with 
each symptom.  Results for Group A barriers to management of symptoms of pain, 
dyspnea, and nausea were the following: 43% reported the inability for family care 
providers to implement or manage recommended treatments and 41% did not want 
recommended treatments (Johnson et al., 2005).  Group B’s two most common barriers to 
management of symptoms of irritability and anger were the following: 53% reported 
families not viewing the symptom as a problem; 47% reported competing demand 
between other symptoms, and 43% of families did not want the implementation of 
recommended treatments (Johnson et al., 2005).  Group C’s barriers to management of 
symptoms pain, dyspnea, and nausea were the following: 43% reported the inability for 
family care providers to implement or manage recommended treatments; 41% did not 
want recommended treatments (Johnson et al., 2005).  According to Johnson and 
colleagues, 43% of hospice nurses reported feeling “often” or “almost always” successful 
in symptom management.  According to symptom management, nurses reported the 
following prevalence relieving specific symptoms: pain (96%), constipation (85%), 
nausea (84%), and least success in relieving hospice patients with weakness (7%), fatigue 
(11%), and anorexia (11%).  Johnson and colleagues reported that nurses were able to 
illustrate success in relieving Group A’s distressful symptoms over both Group B’s and 
Group C’s.  Over (92%) of the nurses reported their hospice organization used a 
guideline or protocol to address specific symptom relief (Johnson et al., 2005).  Nurses 





(75%), Group B (32%), and Group C (33%) (Johnson et al., 2005).  Nurses reported 
various sets of barriers that differed among specific symptoms.  According to Johnson et 
al. (2005), the following two barriers were directly related to specific symptoms within 
each specific group.  In Group A, researchers identified the most prominent symptoms 
(pain, dyspnea, and anxiety) and barriers to effective management as treatment 
implementation and the patient-family-provider triad.  In Group B, researchers identified 
the most prominent symptoms (fatigue, weakness, and anorexia) and barriers to effective 
management as the perception that other more distressful symptoms takes precedence and 
the symptoms were acceptable side effects from other treatment regimens.  In Group C, 
researchers identified the most prominent symptoms (depression, anger, and/or 
irritability) and broader barriers to effective management as inadequate symptom 
identification, insufficient provider knowledge, problems with implementation of 
treatments, and patient or healthcare providers do not believe the symptom is 
problematic.  Johnson and colleagues identified that symptom distress from pain remains 
prevalent and there is a gap in knowledge to design effective symptom management 
interventions specifically targeted to hospice populations.  Data from Johnson and 
colleagues’ (2005) study illustrates the significance of involving hospice healthcare 
professionals, nurses, and caregivers in the development of interventions to manage and 
address potential barriers to effectively improve patient outcomes.  Johnson et al. (2005) 
explained the significance of the intervention to including the triad (patient/care 
giver/provider) on improving in effective communication.  Johnson and colleagues 
(2005) illustrated that the collaboration of perceptions amongst professionals, patients, 





collaborated with various solutions from multiple perceptions.  Johnson and colleagues 
(2005) identified the importance of continuously delivering enhanced education to both 
nurses and family/caregivers.  Both groups benefit from education through improvements 
in comfort care, confidence with implementation of pharmaceuticals and/or standard 
protocols, and overall improvement in patient outcomes with symptom management 
(Johnson et. al., 2005).  Johnson and colleagues (2005) illustrated an effective dyspnea 
intervention that encompassed three steps.  First, focus hospice provider training on the 
assessment and treatment of dyspnea; next, the distribution of written resources to 
patients and/or family caregivers highlighting strategies to manage breathlessness; and 
then, implementation of a dyspnea care plan (Johnson et al., 2005).  Johnson and 
colleagues identified the significance of hospice organizations to establish of a plan of 
care for specific daily symptom measures and provision of follow-up support.  Johnson 
and colleagues (2005) reported 40% of nurses reported pain as their most difficult 
symptom to manage; however, nearly all groups reported success in treatment of pain.  
Strengths of their study included utilization of a large sample size and wide hospice 
representation (Johnson et al., 2005).  Study authors identified one limitation as the 
following: the 15 defined barriers from where nurses choose their selection does not 
entirely capture the importance of perceived barriers (Johnson et al., 2005).  There is 
reporting bias regarding hospice nurses as the only participants and the inherent study 
survey design (Johnson et al., 2005).  Another limitation is barriers were identified for 
specific conditions and do not reflect clusters of multiple symptoms experienced in 
combination.  Johnson and colleagues (2005) illustrated the importance for additional 





improve the quality of life in dying patients.  Johnson and colleagues (2012) were rated a 
3 based on their level of quality through application of the Scottish Intercollegiate 
Guidelines Network (SIGN) criteria (See Appendix A).      
The purpose of this literature review study was to evaluate various combinations 
of medications used in hospice and palliative care patients to optimize symptom control.  
Rose and Currow (2009) identified that hospice’s patients can have a combination of 
symptoms occurring simultaneously.  At times, declining patients lose their ability to 
swallow and an alternative route of drug administration should be effective in managing 
symptoms.  Therefore, the focus of their literature review was to study medications that 
manage symptoms in patients who are unable to take medications orally.  Rose and 
Currow (2009) indicated that a current risk of utilizing combined medications has been 
focusing of the “vitro compatibility studies of new medication combinations” instead of 
analyzing traditional medication combinations.  Medications have the capability to react 
with one another on a molecular basis causing inactive compounds (lessened effect), 
increased risk for toxicity (increased effect), adverse reactions, or visual incompatibility 
(Rose and Currow, 2009).  An interesting fact is that solubility and pH of medications are 
directly related and if effective on one another, a precipitate can be formed (Rose and 
Currow, 2009).  The combination of morphine sulfate, dexamethasone, and haloperidol 
immediately forms an immediate precipitate and causes loss of potency in both 
dexamethasone and haloperidol (Rose and Currow, 2009).  The incidence of chemical 
incompatibility with combining specific medications is considered worse because it is 
non-visible (Rose and Currow, 2009).  There are varieties of drug combinations being 





account the enormous amount of drug combinations already used in current practice 
(Rose and Currow, 2009).  Storing combinations of medication in cool or various 
environments requires the influence of research performed by laboratory chemistry (Rose 
and Currow, 2009).  Rose and Currow illustrated fentanyl remained stable between 5ºC 
and 38ºC for one week.  Midazolam in cooler temperatures decomposed 12% per week 
when stored at 38º.  Therefore, to maintain stability, fentanyl and midazolam could be 
prepared up to seven days prior to use of a refrigerator (Rose and Currow, 2009).  
Additionally, they identified that quality laboratory data is required to strengthen best 
practice in the utilization of combing medications to manage multiple symptoms 
experienced by hospice or palliative care patients (Rose and Currow, 2009).  According 
to Rose and Currow (2009), “chemical compatibility has to be the gold standard and 
systematic inquiry of all the subcutaneous and epidural combinations used in routine 
hospice and palliative care practice.”  The need for additional research on utilizing 
medications in combination is to reduce variations in hospice and palliative care patients 
overall outcome.  Rose and Currow (2009) were rated a 4 based on their level of quality 
through application of the Scottish Intercollegiate Guidelines Network (SIGN) criteria 
(See Appendix A).      
Eighty percent of actively dying patients reported that they experienced pain as a 
symptom in end-of-life-care (Zerzan et al., 2010).  In comparison, Conill and colleagues 
(1997) reported pain does not have a higher prevalence at the end-of-life transition. 
Thirty percent reported pain during the last days compared with 52.3% at the patient’s 
initial evaluation.  In comparison, researchers found that cancer patients, during the end-





(49%) (Tranmer et al., 2003).  Maltoni and colleagues (2012) suggested “palliative 
sedation has been defined as the use of sedative medication to relieve intolerable 
suffering from refractory symptoms by a reduction in patient consciousness, and has been 
one of the most important approaches to refractory symptom control” (p.2830).  The 
clinical decision to implement palliative sedation was utilized to relieve refractory 
symptoms, delirium, existential distress, dyspnea, and pain (Maltoni et al., 2012).  The 
prevalence of these symptoms where palliative sedation was implemented was delirium 
(61.1%), dyspnea (29.2%), pain (20.8%), existential distress (37.5%), and distress (7%) 
(Maltoni et al., 2012).  As indicated by Conill and colleagues (1997) “pain does not have 
a high prevalence at the end of life (30%, during the last days compared with 52.3% at 
the first evaluation” (p.330).   
However, Kutner and colleagues (2007) state that pain (82%) and shortness of 
breath (73%) had high prevalence as a distressful symptoms experienced at the end-of-
life.  In comparison, Johnson and colleagues (2005) wrote that 867 hospice nurses 
reported that out of the frequently selected “difficult to manage” symptoms during end-
of-life transition, each symptom received the following responses: pain (340), dyspnea 
(289), and anxiety (182).  According to Johnson and colleagues (2005) “while 40% of 
nurses selected pain as one of their 5 most difficult to manage symptoms, all reported 
success in treating pain” (p.76).  Multiple symptoms must be treated simultaneously in 
end-of-life care, for example, the treatment of pain coexisting with anxiety or shortness 







Anxiety has been identified as a problematic symptom frequently experienced 
during the end-of-life transition and has been associated with decreased quality of life in 
hospice patients.  Klinkenberg and colleagues (2004) reported that 1 out of every 3 
patients in their research experienced the symptom anxiety with a prevalence of 31% as a 
burden during the last week of life.  According to Conill et al. (1997), a higher prevalence 
of anxiety, at 45.5%, was found to be a distressful symptom over pain at 30.1% in 
patients during their last seven days of life.  However, during the first week assessment of 
these patients, anxiety 50.6% was found with a lower prevalence than pain (52.3%) 
(Conill et al., 1997).  In comparison, Kehl and Kowalkowski (2012) reported across 
multiple studies the weighted prevalence of anxiety had been low at 10.79%.        
2.8 Morphine.   
In a study conducted by Mercadante, Villari, and Casuccio (2010), physicians’ 
knowledge and attitudes regarding hospice, cancer pain, and preferred methods of pain 
were assessed.  The following information was gathered from122 hospices 
geographically located in Italy: provision, medication preferences, preferred route of 
administration, methods to choosing dosage, and choice of BcP medication based on 
opioid administered for background analgesia.  Mercadante et al. (2010) indicated that 
immediate-release morphine may take up to an hour to produce effective analgesic relief 
for patients; furthermore, oral transmucosal fentanyl (OTFC) was shown to be more 
effective than morphine.  Phone interviews with hospice physicians were conducted 





drug of choice, preferred route of administration, method utilized to choose dose, choice 
of BcP medication based on opioid administered for background analgesia, and 
comments.  The data collected by Mercadante and colleagues (2010) was analyzed using 
SPSS Software.  The 122 hospices that participated in the study had a combined total of 
1,375 beds with a mean of 11.2 (± 4.5) beds for each hospice unit.  Oral morphine was 
the drug of choice for BcP; physicians from various hospices reported 93 for morphine 
out of 122 hospice facilities.  The most prominent route of administration was oral 54 out 
of 122 hospices reported.  Appropriate management of BcP enhances the hospice 
patients’ quality of life (Mercadante et al., 2010).   
There are several identifiable threats to validity or limitations to this study.  First, 
geographical bias as the study utilized data from Italy and did not include information 
from other countries.  The sample size was too small.  Another limitation to the study is 
the diverse experience, education, and knowledge of BcP medications by hospice 
physicians.  A larger amount of hospices that participated in the research were from 
Northern Italy in comparison to Southern Italy.  According to Mercadante et al. (2010), 
Italy has an “unequal provision and access to palliative care services across the country.”  
Southern Italy and the islands had fewer hospice organizations “confirming differences in 
economic development” amongst the various regions (Mercadante et al., 2010).  These 
differences interfere with essential statistical comparison OTFC was inaccessible in four 
of the hospices causing an additional limitation.  Mercadante et. al. (2010) were rated a 3 
based on their level of quality through application of the Scottish Intercollegiate 





One study utilized Morphine 50mg/mL administered by route oral, sublingual, or 
bucally and found that oral trans mucosal absorption was 18% effective (Wowchuk et al., 
2009).  Furthermore, Wowchuk and colleagues (2009) identified opioids as the most 
important medication to address symptom management of pain and dyspnea in palliative 
or hospice care.  Care providers used morphine for two of the most recurrent symptoms 
that occur during end-life-of life: pain and dyspnea (Bishop et al., 2009).  Another study 
identified that care providers used morphine most frequently for cancer breakthrough 
pain (Mercadante et al., 2010).  Patients and providers managed breakthrough cancer pain 
mostly with opioids as the chosen rescue medication administered in addition to the 
patients’ continuously scheduled analgesic (Mercadante et al., 2010).  Opioids deliver 
immediate release while morphine may take up to as long as an hour to produce analgesia 
effect (Mercadante et al., 2010).  Palliative sedation widely utilized morphine; Maltoni 
and his team (2012) reported that 87.5% patients received the analgesic morphine.   
2.9 Other Analgesics.   
Hospice physicians that treated breakthrough cancer pain reported oral trans 
mucosal fentanyl (OTFC) in some hospices was unavailable and stated that the choice of 
pain medication should be based on the best cost-efficacy ratio (Mercadante et al., 2010).  
New formulations of fentanyl are proven to be more effective than morphine with a rapid 
onset of analgesic and improved tolerance by patients (Mercadante et al., 2010).  Oral 
trans mucosal fentanyl (OTFC) has been limited in usage due to the issues surrounding 
the cost of the medication (Mercadante et al., 2010).  One study identified 
hydromorphone 10mg/mL injectable preparation was five times more effective than 





vulnerable population who potentially have an increased tolerance to opioids (Wowchuk 
et al., 2009).  In a study by Wowchuk and colleagues (2009), methotrimeprazine 25 
mg/mL was used as a neuroleptic with a broad-spectrum versatility to address pain, 
nausea, and dyspnea in hospice patients during end-of-life symptom management.  
Another study identified five classes of medications commonly used in end-of-life care 
as: opiates, NSAIDS, adjuvant pain medications (tricyclics and anti-seizure medications), 
stimulants, and antianxiety medications (Zerzan et al., 2010).  Opiates were utilized less 
in homes than in established facilities (Zerzan et al., 2010).   
2.10 Anticholinergic.   
One study revealed scopolamine transdermal gel 0.25mg/ 0.1 mL compounded 
addressed the symptom of retained respiratory secretions, they identified the gel’s ability 
for easier dose titration for caregivers, and the positive impact with the rapid onset of 
delivery to patient (Wowchuk et al., 2009).  Atropine, glycopyrrolate, scopolamine, and 
scopolamine derivatives were utilized to address symptomatic crises caused by noisy 
secretions (Kintzel et al., 2009).  This study reported that patients treated with 
glycopyrrolate were much more likely to have a response than those treated with 
scopolamine and two patients reported experiencing hallucinations with atropine 
administration (Kintzel et al., 2009).  Atropine overdose or toxicity has been a potential 
side effect along with rebound sialorrhea, increased heart rate, dysrhythmias, short 
duration of medication effect, and increased effects in debilitated end-of-life patients 
(Kintzel et al., 2009).  According to Kintzel et al. (2009) glycopyrrolate has less effect on 





agency because it satisfied criteria in the treatment of nausea and vomiting (Bishop et al., 
2009).   
2.11 Benzodiazepines.   
Lorazepam 1 mg SL tablets have anxiolytic and sedative properties and can also 
show effectiveness for usage in the treatment of anticonvulsant therapy (Wowchuk et al., 
2009).  In one study, non-topical oral benzodiazepine was utilized to treat agitation 
emergencies in home hospice patients (Bishop et al., 2009).  Palliative sedation for 
controlling of refractory symptoms has been carried out through the physician’s order of 
benzodiazepines administration to patients (Maltoni et al., 2012).  Midazolam (95.8%) 
and lorazepam were the most commonly used benzodiazepines for facilitation of 
palliative sedation (Maltoni et al., 2012).  The most widely utilized benzodiazepine in the 
survey was identified as midazolam (Rose & Currow, 2009).   
2.12 Medications used in Specific Terminal Illnesses.   
One study identified the importance of utilizing the following medications to 
address symptomatic crisis in cancer patients (Sera et al., 2014).  These medications were 
opioids, antipsychotic agents, corticosteroids, and antiemetic agents.  Sera and colleagues 
(2014) indicated terminally ill dementia patients’ medication regimens to control 
symptomatic crisis should have included the following: non-opioid analgesics, 
vitamin/supplements, and antiplatelet.  This study also indicated the importance to 






2.13 Route of Administration.   
A hospice patient’s status can change instantaneously during end-of-life care 
regarding medication requirements for symptoms as well as the route of medication 
delivery (Wowchuk et al., 2009).  Wowchuk and colleagues (2009) identified the 
importance that the route of administration be simplified for administration by families or 
professional healthcare personnel unfamiliar with the utilization of subcutaneous routes.  
Stocked comfort kits in hospice patient’s homes should include the following routes of 
administration: bucally, sublingual (SL), or transdermal (Wowchuk et al., 2009).  Oral, 
sublingual, and rectal were all common pathways for the administration of medications 
found in comfort care kits (Bishop et al., 2009).  There have been several reasons to 
avoid routinely prescribing and dispensing parental medications to hospice patients being 
cared for at home including the relative complexity of administering medications 
intravenously or subcutaneously by lay personnel, and the patient’s preferences to avoid 
injections or pain.  However, according to Bishop and colleagues (2009), at times urgent 
control of escalating pain, severe dyspnea, delirium, or seizures that have been 
complicated symptomatic episodes may require administration route intravenously to 
manage the crises.   
Glycopyrrolate and scopolamine are both medications that were primarily 
effective when administered by subcutaneous route; however, there has been minimal 
data regarding safety usage among the subcutaneous route (Kintzel et al., 2009).  Hospice 
physicians treated breakthrough cancer pain with morphine administered by parentally, 
subcutaneous, or oral administration (Mercadante et al., 2010).  A majority of hospice 





pain in comparison to oral morphine, which had an inappropriate delayed analgesic effect 
(Mercadante et al., 2010).  In palliative care, when the oral route of medication 
administration becomes unavailable due to difficulty swallowing, vomiting, bowel 
obstruction, or decreased level of consciousness the subcutaneous route of administration 
for medication has been preferred (Rose & Currow, 2009).  Rose and Currow (2009) 
identified that when specific delivery of medications through transdermal, intranasal, 
nebulized, rectal, or sublingual administration was unattainable, subcutaneous 
administration of medication has been the most widely utilized route of long-term 
administration.  Regular subcutaneous route avoided problems with recurrent intravenous 
cannulation, had a positive depot effect, and allowed the delivery of medications in bolus 
or by continuous infusion (Rose & Currow, 2009).  The transdermal route was not 
recommended with medications such as methotrimeprazine, cyclizine, chlorpromazine, 
prochlorperazine, trifluperazine, and diazepam because they caused skin reactions during 
administration (Rose & Currow, 2009).     
2.14 Comfort Care Kits.   
Comfort care kits have had a variety of specific medications employed to control 
problematic symptoms or crisis such as pain, dyspnea, anxiety, agitation, nausea, or fever 
that occurred among hospice patients.  Caregivers utilized comfort care kits for the 
escalation of distressing symptoms and crisis admissions to hospice (Wowchuk et al., 
2009).  Wowchuk and colleagues (2009) explained that comfort kits contain 
pharmaceuticals commonly required in the final days of life to manage symptomatic 
crises.  Administrators chose the medications for inclusion in the kits carefully based on 





care patients (Wowchuk et al., 2009).  The medications included in comfort care kits 
were the following: opioid and non-opioid analgesic, antiemetics, corticosteroids, 
laxatives, and antipsychotics (Sera et al., 2013).  Medication kits for symptomatic 
episodes placed in hospice patients’ homes have been an essential initiative to maintain 
quality comfort care in this vulnerable end-of-life population (Wowchuk et al., 2009).  
Eighty percent of those hospice patients who desired to spend their last days at home 
used palliative medication kits and were able to achieve the desired outcome by being 
able to have experienced death at home (Wowchuk et al., 2009).   
Hospice patients utilized comfort care kits when experiencing episodes of 
distressing symptoms.  When the patient experienced a symptomatic crisis, the caregivers 
at the residence were able to administer a rescue medication after they notified the 
hospice agency.  The nurses educated the caregiver regarding which symptoms to address 
with comfort care kits including pain, dyspnea, nausea/vomiting, seizures, acute anxiety, 
agitation/delirium, noisy secretions, and fever.  According to Bishop and colleagues 
(2009), noisy secretions and fever were additional symptoms identified; medications used 
were an anticholinergic for secretions, such as atropine or hyoscyamine, and 
acetaminophen for patient’s fever.  Experiencing symptomatic crisis during the end-of-
life transition can be devastating to both patients and their loved ones.  The terms used by 
hospice agencies to describe the comfort kits included the following: emergency kit, 
symptom relief, relief kit, and comfort (Bishop et al., 2009).  Hospice initiated these 
medications through comfort care kits left at the patient’s residence for emergent 






2.15 Patient and Caregiver Education.   
Many hospice patients rely on care administered by a family member or person 
without medical experience.  Hospice agencies must educate caregivers on the 
medication regimens and medications that address the individual patient’s symptomatic 
crisis as needed.  According to Kehl and Kowalkowski (2012), in home hospice, patients’ 
informal caregivers are their primary care providers for complicated symptom 
management.  These families reported feeling unprepared for these multi-symptom 
changes that occurred during the last two weeks of the patient’s life.  According to Kinzel 
et al. (2009), adverse events in hospice patients were difficult to identify because hospice 
did not implement routine monitoring of vital signs and laboratory tests; furthermore, 
patients were often unconscious prior to death.  If a hospice patient’s symptoms were 
unable to be controlled, the caregiver most often sought treatment for crisis at a local 
emergency room.       
A study identified the significance to maximize symptom control in end-of-life 
patients through establishment of a clear plan of care involving the provision of 
comprehensive education to both end-of-life patients and their caregivers (Wowchuk et 
al., 2009).  According to Conill and colleagues (1997), it is essential to provide 
information and facilitate appropriate communication regarding the appearance of 
probable symptoms to reduce distress for both the patient and their caregivers.  Kits 
should be kept in secure locked containers to address short-term symptomatic episodes, 
imminent death, or until access to pharmacies becomes available (Wowchuk et al., 2009).  
Reports given by caregivers surveyed revealed feelings of non-preparedness and the 





to use to alleviate symptomatic crisis (Wowchuk et al., 2009).  Wowchuk and colleagues 
(2009) suggested “dying is a natural process, combined with complications, distressed 
caregivers’ loss of control, impaired communication, and lack of structure to facilitate 
coping with the approaching death in a proactive manner” (p.800).  Healthcare providers 
in hospice agencies should have actively discussed terminal symptoms with hospice 
patients and their caregivers.     
 One study actively discussed what to expect, what symptoms occurred, how to 
approach the management of particular symptoms, reduce anxieties, and decrease the 
occurrence of hospitalizations in the hospice patient population (Wowchuk et al., 2009).  
A similar study demonstrated that hospice agencies must guarantee to patients and their 
families that symptoms experienced by the hospice patients will be addressed within the 
established plan of care (Bishop et al., 2009).  Hospice agencies should provide 
educational handouts to the caregivers, patients, and their families illustrating the 
potential symptoms that commonly occur during the end-of-life transition.   
Being able to identify the symptom and knowing how to treat symptomatic crises 
in hospice patients can improve outcomes and reduce anxieties surrounding death.  One 
example, from Kintzel et al. (2009), stated it was effective to teach caregivers the 
interventions to utilize when noisy secretions occurred.  Kintzel and colleagues (2009) 
reported placing patients in a semi-prone position, administering anti-secretion therapy, 
and at times, gentle suctioning was required.  Subcutaneous administration placed fewer 
responsibilities on caregivers that administered medication and was convenient and 





crisis prevention, preparation, and ongoing education appear to be a consistent finding in 
all relative literatures utilized in the search.      
2.16 Cost Effectiveness.   
One of the two prominent reasons for emergent admissions to hospice or hospitals 
during end-of-life care has been poor symptom control, caregiver role strain, or the 
caregivers’ inability to manage the hospice patient at home due to the increased 
complexity (Wowchuk et al., 2009).  The study tried to illustrate that the utilization of 
kits in terminally ill hospice patients has been both cost effective and cost efficient 
(Wowchuk et al., 2009).  According to Wowchuk et al. (2009), “this notion has been 
echoed in other studies, high lightening that “making do” with the available medications 
in the home versus having immediate access to appropriate pharmaceuticals to control 
symptoms in the last days of life has been a commonly emerging concern that greatly 
contributes to unplanned hospital admissions” (p.798).     
Researchers identified that kit utilization often avoided hospitalizations or 
emergency room visits and could strategically impact the cost involved in the delivery of 
quality care (Wowchuk et al., 2009).  In one retrospective survey study, 12 programs out 
of 16 estimated the cost of comfort care kits were less than $50 and four agencies 
estimated cost greater than $50 (Bishop et al., 2009).  Compared to the cost of emergency 
room invoices and the cost of emergency transport, which according to Hatley and 
Patterson (2007) could cost from $415 to $1,218 or more depending upon the locale, $50 





identified that hospices cover the cost of enrolled patients and may have incentives to use 
less expensive medications to treat symptoms (Zerzan et al., 2010).   
      It has been important for hospice programs to provide all of the following 
interventions: quality comfort care; caregiver education regarding medications; and 
strategies for cost effectiveness.  Readily accessible comfort kits for hospice patients can 
potentially avoid extraneous costs resultant of emergency room visits and EMS transport 
due to episodic symptom crises.  According to Bishop et al. (2009), “eighteen agencies 
(85%) reported the kits often averted hospital or emergency department visits and two 
(10%) said that the kits occasionally avoided such visits” (p.40).  Bishop and colleagues 
(2009) showed that complications occurred when relieving symptomatic crisis to hospice 
patients located in geographical rural communities.  Many rural areas do not have access 
to pharmacies that are open twenty-four hours.  Therefore, the evidence supports the 
implementation of comfort care kits in hospice patient’s homes to ensure quality 
symptom management and avoidance of ER visits due to symptomatic crisis. 
2.17 Synthesis 
After the analysis of research articles (See Appendix F), the synthesis identified 
supporting evidence that multiple medications or interventions should be used to manage 
multiple symptoms at the end-of-life transition.  The analyses of the selected articles were 
pertinent to improving clinical practice with multi-symptom management in end-of-life 
care.  This synthesis found sufficient evidence to support the implementation of comfort 
care kits for symptomatic crisis and delivery of continuous education in hospice patients’ 





Evidence demonstrated that patients experience multiple symptoms during the 
end-of-life transition (Bishop et al., 2009; Conill et al., 1997; Johnson et al., 2005; Kehl 
and Kowalkowski ,2012;  Kintzel et al., 2009; Klinkenberg et al., 2004; Kutner et al., 
2007; Maltoni et al., 2012; Rose and Currow, 2009; Sera et al., 2014; Tranmer et al., 
2003;  Wowchuk et al., 2009; Zerzan et al., 2010).  Of the evidence reporting 
symptomology the ratings were as follows: one study was graded 1+, five were graded as 
2+, one was 2-, five of the studies were 3; and two of the studies were graded 4.     
2.18 Summary 
Multi-symptom management has been identified as frustration for both the 
patients and their caregivers. The literature has shown that ready access to rescue 
medications and education on administration can potentially alleviate the distressing 
symptoms and produce a positive outcome for the patient and caregivers.   
Furthermore, patients in hospice care can experience multiple symptoms and 
complications; therefore, healthcare providers must be educated on the use of multi-
symptom management and continuously review medication regimens based on the 
patient’s current health status.  For example, studies identified that hospice patients’ 
ability to swallow medications can diminish rapidly and route of administration may need 
to be changed. 
According to the literature, the most common multi-symptoms among hospice 
patients are pain, dyspnea, nausea, delirium, and increased secretions.  Morphine was 
used to treat both pain and dyspnea and was the most effective (Bishop et al., 2009; 





Another analgesic proven to be effective was oral trans mucosal fentanyl (Mercadante et 
al., 2010).  However, it was not a cost effective choice when compared to morphine 
(Mercadante et al., 2010).   
The anticholinergic glycopyrrolate was shown to decrease secretions in hospice 
patients without the side effects caused by atropine (Kintzel et al., 2009).  The 
benzodiazepine midazolam was the most effective to ameliorate the symptoms of anxiety 
or agitation (Maltoni et al., 2012; Rose & Currow, 2009).   
Multi-symptom management is important to quality of life and reducing 
extraneous costs for patients such as emergency room visits.  The literature supports that 
quality of life was improved and costs were reduced with multi-symptom management by 
healthcare providers and caregivers (Bishop et al., 2009; Rose & Currow, 2009; Sera et 
al., 2014; Tranmer et al., 2003; Wowchuk et al., 2009; Zerzan et al., 2010). 
2.19 Recommendations 
Based on the evidence illustrated from the selected studies, this review identified 
these recommendations to assist hospice agencies in improving the quality of care 
delivered during the end-of-life transition.  These recommendations have been graded 
according to the Michigan Quality Improvement Consortium (2008) system (see 
Appendix B).  They are based on the quality and amount of evidence available to support 
the recommendation for guidelines, practice parameter, or clinical policy.  
1.)  Manage multiple symptoms in hospice patients’ that increase during the end-of-
life transition Evidence Grade A. Assess and report changes in hospice patients.  





research to help identify the best treatments to utilize during episodes of pain crises in 
hospice patients during the end-of-life transition (Sera et al., 2014; Zerzan et al., 2010).  
2.)  Maintain a symptom-free environment for patients and their families.  Evidence 
Grade C. Access to a pharmacy that operates 24 hours a day and never closed on 
holidays is required by all hospice agencies.  In addition to dispensing oral or rectal 
medications for breakthrough symptom treatment, it is sensible for hospice agencies to 
develop the capacity to administer parental medications and guide further research to 
determine effectiveness of topical preparations for symptom management as shown by 
Bishop et al. (2009).   
3.)  Provide education to the providers, caregivers, patients, and their families 
illustrating the potential symptoms that commonly occur during the end-of-life 
transition.  Evidence Grade C. Continuous provider, patient, and caregiver education 
on symptomatic crisis management improves the delivery of hospice care.  Wowchuk et 
al. (2009), identified the significance to maximize symptom control in end-of-life patients 
through establishment of a clear plan of care involving the provision of comprehensive 
education to both end-of-life patients and their caregivers.   
Kehl and Kowalkowski (2012) determined that both professional and informal 
caregivers need an understanding of what signs and symptoms to expect as death 
approaches.  It is significant to improve assessment and management of commonly 
identified symptoms that occur during the end-of-life transition.  According to Wowchuk 
et al. (2009), caregivers reported insecurity and insufficient information as main causes of 





greater chance of enhancement when programs provide education on a continuous basis.  
Wowchuk et al. (2009) recommend providing caregivers with a realistic portrayal of 
challenges or complications they might encounter while caring for hospice patients.  
They discussed what to expect, what symptoms occurred, how to approach the 
management of particular symptoms, reduce anxieties, and decrease the occurrence of 
hospitalizations in the hospice patients’ population (Wowchuk et al., 2009).   
4.)  Generate evidence to support consistent kit protocols that might facilitate 
improved symptomatic crises among the terminally ill population throughout any 
patient environment. Evidence Grade C.  According to Bishop et al. (2009) 
prospective surveillance studies on frequency of EMS transport, ER visits, and general 
inpatient hospital due to treatment of acute symptoms of pain, dyspnea, nausea, seizures, 
acute anxiety, or agitated delirium by hospice patients would be useful to frame the scope 
and extent of these clinical problems (p.42).  
2.20 Implications 
 This quality improvement project based implications on conclusions and provides 
suggestions for implementing findings to clinical knowledge, practice, and changes to 
current policies (Burns & Grove, 2009).  Current evidence has shown that the 
implementation of comfort care kits must be introduced at all levels of practice including 
both clinical and policy development. 
2.21 Implications for clinical education.   
In order to maintain comfort for the patient during the end-of-life transition, 





and caregivers regarding the prognosis and therapeutic interventions.  Hospice clinicians 
must assess patients during multiple visits throughout the week, especially when a patient 
status has been identified as declining.  Clinicians must also recognize the importance of 
multi-symptom management and be able to recognize signs and symptoms of imminent 
death in order to prepare both the patient and their loved ones.  For example, hospice staff 
must be educated regarding how patients can lose their ability to swallow during 
imminent death and how proper delivery of medication has a serious impact on the 
patients overall symptom management during the end-of-life transition. 
2.22 Implications for Practice.   
Implication for symptomatic management in hospice practice was shown as the 
use, clinical efficacy, cost effectiveness, and impact of medication kit availability on 
hospice patients and their caregivers (Bishop et al., 2009).  Further research was needed 
to illustrate that retained or excess secretions can affect the successful and accurate 
sublingual dose administration for any particular medication (Kintzel et al., 2009).  
Hospice practice should identify the healthcare providers’ choice of prescribing 
medication and the comfort in use of opiates to treat patient symptoms (Zerzan et al., 
2010).  A limitation for subcutaneous route administration was identified by the invisible 
chemical incompatibilities that appeared in literature as continuous subcutaneous 
infusions become more prevalent in the treatment of symptoms during the end-of-life 
transition (Rose and Currow, 2009).   
 Bishop et al. (2009) highlights another significant issue for hospice practice.  





emergencies for hospice patients located in rural geographical areas.  Variables affecting 
patient’s level of comfort management are dependent on factors such as the distance the 
hospice nurses have to travel to patient’s residence, the road conditions encountered on 
the route to the patient’s residence, and the adverse weather conditions or travel 
conditions overall (Bishop et al., 2009).  Another implication for practice was the impact 
that rural pharmacies can have on an agency’s ability to obtain essential medications for 
hospice patients.  The rural pharmacy’s medication supply, selections/variety, and ability 
to compound medications can influence the patient’s overall treatment. 
2.23 Implications for Policy Development.   
Implications for policy development include federal regulations by Medicare 
requiring hospice programs to make provisions to prevent and manage crises as a 
condition for participation in the Medicare Hospice Benefit program (Bishop et al., 
2009).  The hospice benefit allows the patient and family to stay in the comfort of their 
home unless an inpatient admission has been shown necessary (Centers for Medicare & 
Medicaid Services, 2013).  Hospice agencies have been required by law to monitor and 
report patient care processes and outcomes in order to improve quality measures for 
persons at the end of life.  In 2008, the Center for Medicare & Medicaid Services (CMS) 
federally required all hospice programs to implement Quality Assessment and 
Performance Improvement Programs that have been data driven, systematic approaches 
to improve the delivery of care provided by all hospices (Scheck, Rokoske, Durham, 
Cagle, & Hanson, 2010).  CMS contracted with Quality Improvement organizations 
located in both North and South Carolina to create quality measures and instruments to 





been mandated by federal law to identify any areas that need improvement and to 
strategically develop process improvement plans to enhance the delivery of care 
(Schenck et al., 2010).  The National Consensus Project for Palliative Care identified 
eight domains and corresponding practice guidelines for high quality care for patients at 
end of life (Schenck et al., 2010).  This was adopted by National Quality Forum and 
updated in 2009 as a guideline that targeted many domains including care of the 
imminently dying patients (Schenck et al., 2010).  Therefore, they provided the hospice 
clinicians with ways to evaluate patients’ responses to assigned treatments for symptom 
management (Schenck et al., 2010). 
2.24 Summary 
 Managing symptoms in hospice patients can be complicated and requires an 
active approach by all individuals involved in the delivery of care to this vulnerable 
population.  Comfort care kits should be implemented to every home hospice patient as 
an intervention to improve the patients’ comfort during the end-of-life transition.  This 
active approach to delivering quality care for hospice patients can potentially increase 
quality measures and outcomes in symptomatic management.  However, additional 
research has been identified as a necessity to determine the use, clinical efficacy, cost 
effectiveness, and impact of comfort kits for symptomatic management.  Other areas for 
future research include the influence of retained or excess secretions on sublingual 
administration of medication, a better understanding of injectable combination 
medications, and the significance to rural hospice patient’s treatment of a local and 
accessible pharmacy with adequate supply and selection.  Further evaluation of the 











Chapter 3 Design 
Hospice and palliative care organizations promote the delivery of comprehensive 
comfort care to enhance their patients’ quality of life during their end-of-life transition.  
Patients experience various distressful physical symptoms other than pain alone during 
the last phases of life and distressful symptoms often negatively effective a patient’s level 
of comfort during this time transition (Bishop et al., 2009; Conill et al., 1997; Johnson et 
al., 2005; Kehl and Kowalkowski, 2012; Kintzel et al., 2009; Klinkenberg et al., 2004; 
Kutner et al., 2007; Maltoni et al., 2012; Rose and Currow, 2009; Sera et al., 2014; 
Tranmer et al., 2003;  Wowchuk et al., 2009; Zerzan et al., 2010).  It is evident that 
morphine is a prominent medication utilized for symptom relief during end-of-life care.  
However, morphine does not relieve various symptoms such as shortness of breath 
experienced during the dying process and can even potentially cause distressful 
symptoms from common side effects of opioid administration.  A clinical challenge to 
enhancing the delivery of end-of-life care is to have the proper cadre of medications 
readily available during end-of-life that health care providers can utilize for multi-
symptom management.   
Best practices suggest that the cadres of medications be available to family 
members and the patients’ caregivers for ready use.  However, data warrant further 
review to determine which medications are best for managing end of life transitions, 





organizations are now federally mandated by Section 3004 of the Patient 
Protection and Affordable Care Act (ACA) to submit quality data through the Hospice 
Quality Reporting Program (HQRP) based on the most current HIS (Hospice Item Set) 
(CMS, 2015).  Failure to submit quality data or meet HQRP requirements result in a 2 
percentage point reduction in the hospice organizations Annual Payment Update.  In 
2014, Pain Measure had been the prominent symptom required to be assessed on 
admission and reported.  However, as of 2015, the following quality measures are 
calculated utilizing the CMS (HIS): patients treated with an opioid who are given a bowel 
regimen; pain screening, pain assessment; dyspnea screening; dyspnea treatment; 
treatment preferences (CMS, 2015).    
Application of Stetler’s Model, utilization of the model developed by Johnson et 
al. (2005) Symptom Distress Model (Appendix C) in combination with key components 
of the literature synthesis will be used as the framework for this quality improvement 
project.  The purpose of this project is to compare the provider’s perceptions following an 
educational model of symptom management methods (single symptom management 
versus multi-symptom management) for improving the quality for hospice patients during 
the end-of-life transition.     
3.1 Design 
A descriptive survey pre and post-test design will be used to collect and analyze 
data from hospice nurses, medical directors, and clinical nursing directors’ perceptions 
from their professional experience concerning a conglomerate of variants that effect the 





understanding of the provider’s perceptions of using of comfort care kits in hospice care 
for single symptom versus multi-symptom management for improved patient outcomes. 
The survey consists of 8 questions and contains the following sections:  what is the 
perception of symptoms among care providers/givers, which are the most prominent 
distressful symptoms experienced by hospice patients, and the pharmaceutical preference 
to treat distressful symptoms.    
3.2 Instruments 
The DNP project author developed a survey instrument based on the synthesis of 
the evidence in Chapter II, of which the survey has not been tested for reliability or 
validity.  The instrument consists of eight items and contains the following sections: what 
is the perception of symptoms among care providers/givers, which are the most 
prominent distressful symptoms experienced by hospice patients, and the pharmaceutical 
preference to treat distressful symptoms.   The purpose of the survey is to glean a better 
understanding of the provider’s perceptions of using of comfort care kits in hospice care 
for multi-symptom versus single symptom management for improved patient outcomes.  
The survey was administered pre and post intervention to approximately 30 Clinical 
Nursing Directors, Licensed Practical Nurses, Medical Directors, and Clinical Nurse 
Supervisors, all of whom are employed in Hospice Care Organizations in SC.  These 
participants accessed an electronic or paper survey at their home or office or by personal 








  Approximately thirty (n = 30) Clinical Nursing Directors, Licensed Practical 
Nurses, Medical Directors, and Registered Nurse Case Managers from hospice 
organizations located in South Carolina were surveyed pre and post intervention 
regarding their perception of symptoms, the most prominent distressful symptoms that 
are experienced by hospice patients, and the pharmaceutical preference to manage 
distressful symptoms.  Inclusion criteria included: currently employed by one of the five 
hospice organizations, currently hold an active healthcare professional license in the state 
South Carolina, are over age 18, use English as a first language, and have access to a 
computer or smart phone with Internet capability.   
3.4 Setting 
Participants were recruited from five SC hospice organizations that are state and 
federally regulated to conduct hospice care.  The five offices are located in Columbia, 
Greenville, Newberry, and Union Counties.  Clinical Nursing Directors, LPNs, Medical 
Directors, and RN Case Managers accessed the electronic survey or hardcopy at their 
designated home office or by their personal computer or personal smartphone with 
internet access pre and post testing.  Class Climate and SAS captured data.   
3.5 Procedures 
Following Institutional Board approval, data collection occurred pre and post 
testing by Class Climate.  A list of potential study participants was derived from email 
addresses supplied by each participating hospice organization.  The survey was 





participants by email or hard copy.  Study participants completed the pre-test online and 
no personal identifiers were linked to the study participant.  Participation was completely 
anonymous and completing the pre-test survey online or by hardcopy implied consent.   
Once the pre-test was administered over a two (2) week period, hospice 
employees from all five hospice organizations participated in an educational presentation 
that contained information regarding comfort care kits and managing single versus multi-
symptoms in hospice patients.  The educational module consisted of one 30 minute 
session taught by the investigator.  The components of the educational module included 
the following: a handout identifying common EOL signs and/or symptoms, definition of 
Comfort Care Kits, common medications prescribed in kits, and verbal explanation of 
this quality improvement project.  Approximately two (1) weeks was needed to reach all 
five hospice organizations and employees for implementing the educational module.  
Educational sessions for staff were mutually arranged by the study author and each 
hospice care organization.  Dates, times, and rooms for the educational sessions were 
arranged through each facility Hospice Clinic Director but conducted at the facility to 
minimize employee disruption and travel.  Any multimedia tools or handouts used for the 
educational module were supplied by the study author.   
Once all five participating hospice organizations and employees received the 
educational module, the investigator administered post two (2) weeks the post-test using 
the Class Climate method.  The post-test was identical to the pre-test and was not being 
linked to any personal identifiers.  Participation was completely anonymous and 
completing the post-testing survey online or by hardcopy implied consent.  Table 3.1 









Obtain IRB approval 
 
Week One: February 1, 2016 
Obtain Emails from HR Hospice. 
Administer Pre-test by Survey Monkey 
Week One to Two: February 1-February13 
Conduct Educational Module 
 
Week Three-Four: February 14-Feburary 
27 
Administer Post-test  
 
Week Five-Six: February 28-March 5 
 
3.6 Description of intervention 
The intervention, educational session, consisted of a single 30 minute module on 
the use of comfort care kits for multi-symptom management versus single symptom 
management for hospice patients.  The presentation contained information on signs and 
symptoms that have been commonly encountered by hospice patients and cause 
discomfort.  The handouts reinforced the importance in recognizing common signs and 
symptoms.  The information also addressed which medications are used to treat 
symptoms commonly experienced in end-of-life care.  Following the intervention, the 
healthcare participants were allowed to ask any questions related to the content.  A hard 
copy of the quality improvement project and corresponding handout (Appendix D) were 
left in the conference room to be accessible to hospice healthcare providers interested in 







3.7 Data Analysis methods 
The Class Climate and SAS programs was utilized to capture data for statistical 
analyses and then imported for descriptive data such as frequency tables; using SAS to 
conduct frequency distribution tables.  The data was analyzed for differences between pre 
and post-testing to determine changes in perceptions, if any, of care providers in the use 
of single symptom management versus multi-symptom management in hospice patients 
transitioning to end-of-life.  Dr. Abbas Tavakoli provided statistical support, expertise for 
analyses, and data management for importing data into Excel files.  
3.8 Framework/model of research: Stetler’s Model  
Stetler’s model has been used by first preparing the hospice registered nurses and 
other healthcare providers by making sure the agency was ready for systematically 
conducting a search for relevant evidence in practice (Melnyk & Fineout-Overholt, 
2011).  Stetler’s second phase was used to assess a body of evidence, summarize the 
evidence for quality and validity, and identify a need through the systematic collection of 
evidence (Melnyk & Fineout-Overholt, 2011).  Phase three was used to compare the 
responses from the survey and evaluate if the intervention combined with the guidelines 
proposed a change to current practice.  The fourth phase of Stetler’s model was used 
show translation or application of the intervention, with the implementation of placing 
comfort care kits instead of using only morphine alone with the hospice patients (Melnyk 
& Fineout-Overholt, 2011).  In phase five, evaluation of the plan to improve emergent 





care kits before their end-of-life transition will be implemented and evaluated (Melnyk & 
Fineout-Overholt, 2011). 
Johnson et al. (2005) developed and utilized a basic theoretical Symptom Distress 
Model.  The Symptom Distress Model is defined in the 5 following steps: symptom 
recognition; symptom assessment; care plan design; implementation; and reassessment 
(Johnson et. al, 2005).  This model can be utilized by the participating hospice healthcare 
providers as a tool during their daily patient encounters with symptoms.   
3.9 Strategies to reduce barriers and increase supports 
The influential participants in hospice agencies to present the information for 
change will be the board of directors, medical directors, and hospice clinicians.  A barrier 
was the ease and accessibility of medications in a comfort care kit that can potentially be 
abused by the home hospice patient’s caregiver.  A strategy to reduce this barrier and 
increase support is to place comfort care kits in locked boxes of care givers that are 
suspected drug abusers.  The registered nurse can unlock the box and administer the 
comfort medications when an emergent crisis evolves.        
Another strategy that will increase support is to demonstrate to the hospice 
agency’s board of directors, medical directors, and clinicians the cost effectiveness and 
accessibility of emergent symptomatic medications to achieve comfort in end-of-life care.  
Comfort care kits target the complicated symptomatic management that occurs after 
hours.  Some home hospice patients live in rural areas and the nearest twenty-four hour 
pharmacy can be up to hour away from their residence.  Therefore, another strategy will 





comfort medications to alleviate symptoms. This quality improvement project data was 
given to the influential members at the hospice agency.  It was identified as a cost 
effective measure to utilize comfort care kits for emergent symptom crisis during end-of-
life transition due to the increased cost of unscheduled on call nursing visits, 
inaccessibility of twenty-four hour operating pharmacies, and unnecessary emergency 
room visits.  The strategic process for implementing this intervention can be addressed 
with the most significant emphasis on providing quality comfort care to home hospice 
patients during symptomatic crisis.   
3.10 Summary 
Management of symptoms related to the end-of-life care in hospice patients can 
be complicated and requires an active approach by all individuals involved in the delivery 
of care to this vulnerable population.  These comfort care kits are used to manage multi-
symptoms in home hospices patients and can improve patient comfort.  Comfort care kits  
also reduces unnecessary on-call nursing visits, unscheduled visits to deliver medications, 
improved prevention of emergency room visits, and are cost effective.  Comfort care kits 
with multi-symptom management should be implemented to every home hospice patient 
as an intervention to improve the patients’ comfort during the end-of-life transition.  This 
active approach to delivering quality care for hospice patients can potentially improve 







Chapter 4 Results 
 
4.1 Description of Sample 
 
Out of the thirty Clinical Nursing Directors, Licensed Practical Nurses, Medical 
Directors, and Registered Nurse Case Managers from South Carolina hospice 
organizations, twenty-three responded (response rate was 77%) to the pre-test and post-
test survey regarding their professional expertise and perceptions for single versus multi 
symptom management for end-of- life care in hospice patients.  Pre and post intervention, 
participants were surveyed regarding their perception of symptoms, the most prominent 
distressful symptoms that are experienced by hospice patients, and the pharmaceutical 
preference to manage distressful symptom(s). The final sample (n = 23) was comprised of 
healthcare providers who were on call 24 hours per day, were employed by hospice 
organizations located in from Chapin, Columbia, Greenville, Irmo, Newberry, and Union, 
South Carolina, and delivered one-on-one care to hospice patients geographically located 
in rural and urban areas, albeit at home or at facilities.   
 
 
4.2 Analysis of research questions 
 
Table 4.1 depicts the participants’ responses’ to the pre-test survey.  Frequency 
distribution tables are used for numeric variables.  They summarize the distribution of 
values from the sample population.  According to the hospice providers’ pre-test 
responses, pain (35%) was the most prominent symptom witnessed by a provider during a 





distressful symptom witnessed by providers during a patient’s last two weeks of life.  
Anxiety/restlessness and increased respiratory secretions were the most distressful 
symptoms for patients’ families and/ or caregivers during a patient’s last two weeks of 
life (35%) (Table 4.1).   
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Table 4.2 depicts the participants’ responses’ to the additional components of the 
pre-test survey.  Hospice providers’ response rates regarding the most common 
medication utilized to address anxiety/restlessness during the end-of-life was oral 
Lorazepam.  However, some participants reported using topical compound as opposed to 
the oral route.  When providing relief for increased respiratory secretions, hospice 
providers’ responses were divided amongst administering atropine (55%) or scopolamine 
transdermal patch/gel (46%).  Morphine was reported as the pharmaceutical of choice to 
alleviate dyspnea/SOB and/or pain by all hospice providers.  
 
Table 4.2 Pre-test Survey Frequency Distributions 
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Post Test survey, Table 4.3 data illustrates the provider’s perceptions regarding 
common symptoms experienced at the end-of-life in patients.  According to the hospice 
providers’ responses, dyspnea/SOB (30%) was the most prominent symptom during a 





the most distressful symptom for patients during a patient’s last two weeks of life.  
Increased respiratory secretions (44%) was the most distressful symptom for patients’ 
families and/ or caregivers to witness during a patient’s last two weeks of life.   
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Table 4.4 depicts the participants’ responses’ to the post-test survey which 
described providers’ choices of medications in managing symptoms during the patient’s 
last two weeks of life.  There were some differences from the pre-test responses. Post 
testing, oral Lorazepam (78%) was reported as the most frequently administered 
medication to alleviate anxiety in hospice patients during the end-of-life transition.  In the 
post-test survey, participants’ response rate for using a topical benzodiazepine during the 
end-of-life care decreased.  Morphine was reported the most prominent medication given 
in the last two weeks of a patient’s life, however, some participants responses changed 
and included other (4%).  Additionally, a variety of pain medications were reported being 
administered by hospice providers during the end-of-life transition.  Whereas, prior to the 
educational module, the pre-test, only Morphine was reported as the choice of analgesic 
to relieve pain.  
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Frequency distributions were calculated for pre and post-test for each question for 





distressful symptoms and the providers’ perceived preferred method of treatment to 
alleviate the symptom.  In summary, results showed differences in responses between 
pre-test and post-test.   
On the pre-test, hospice providers reported the most prominent symptom during 
the end-of-life was pain (35%) followed by dyspnea/SOB (22%).  Whereas, the responses 
on the post-test indicated dyspnea/SOB (30%) followed by pain (22%).  There was an 
increase by 10% in participants reporting anxiety/restlessness as a patient’s common 
symptom in post-test results (26%).   
Healthcare providers reported the most distressful symptom for the patient was 
dyspnea/SOB (44%) on both the pre-test and post-test.  However, an 8% decrease was 
demonstrated among providers in reporting pain as most distressful symptom from pre-
test (17%) to post-test (9%).  Additionally, a 9% frequency increase was noted among 
providers reporting the presence of increased respiratory secretions from pre-test (13%) 
to post-test (22%).  The hospice providers’ response rate for the most distressful 
symptom for the patient’s families or caregivers to witness demonstrated a 9% increase in 
the presence of increased respiratory secretions from pre-test- (35%) to post-test (44%).   
The hospice healthcare providers’ response rate on specific medications utilized 
to alleviate symptoms did not identify differences among response rates from pre to post 
test.  Oral Ativan was the preferred method to alleviate anxiety/restlessness while 
morphine was used to alleviate dyspnea/SOB.  Providers used atropine as the preferred 
method of treatment for respiratory secretions (pre-test 55% and post-test 59%).  
Scopolamine transdermal patch pre-test (46%) was used a major medication for 





preferred method to alleviate pain and the medication predominantly used the most to 
improve patient’s level of comfort or outcome due to distressful symptom.   
4.4 Summary 
After the educational module, frequency data indicated that the perceptions of 
end-of-life care amongst providers was more encompassing for multi-symptom 
management versus single symptom management “pain”.  This data is consistent with the 
evidence based literature that demonstrates that providers should be more inclusive of 
multiple symptom management than single symptom management for improved 
outcomes during the end-of-life care for hospice patients.  Educational Models in formal 






Chapter 5 Discussion 
 
5.1 Recommendations for Practice  
 
According to the quality improvement project and consistent with the literature, 
comfort care kits should be delivered to hospice patients on admission with a plan that 
includes multi-symptomatic management in hospice practice for improved patient 
outcomes.  Findings from the project underscored the need for providers to use multi-
symptomatic management for improved outcomes with clinical efficacy, cost 
effectiveness, and an overall positive impact of medication kit availability on hospice 
patients and their caregivers (Bishop et al., 2009; Rose & Currow, 2009; Sera et al., 2014; 
Tranmer et al., 2003; Wowchuk et al., 2009; Zerzan et al., 2010).  Comfort care kits 
contain medications that address multiple symptoms including pain, dyspnea, 
nausea/vomiting, anxiety/restlessness, agitation/delirium, noisy secretions, and fever.   
The implementation of multi-symptom management guidelines integrate 
standards of care in clinical practice for managing multiple symptoms with improving 
quality of life during end of life transition (Anderson & Chojnacka, 2012; Wowchuk et 
al., 2009).  Placing a comfort care kit into the patient’s environment is a preventative 
measure to improve their quality of life.  This is especially significant when hospice 
providers admit a patient who expires in less than twenty-four hours.  Utilizing 





quickly, effectively, and results in improved outcomes and better standards of care 
(Anderson & Chojnacka, 2012; Kinley et al., 2013)  Currently, there are increased 
challenges to effectively managing symptomatic emergencies for hospice patients located 
in rural geographical areas.  Variables affecting patient’s level of comfort management 
are dependent on factors such as the distance the hospice nurses have to travel to a 
patient’s residence, the road conditions encountered on the route to the patient’s 
residence, and the adverse weather conditions or travel conditions overall (Bishop et al., 
2009).  Another implication for practice was the impact of rural pharmacies limitations 
can have on an agency’s ability to obtain essential medications for hospice patients.  The 
rural pharmacy’s hours of operation, medication supply, selections/variety, and ability to 
compound medications can influence the patient’s overall treatment.  Therefore, the 
implementation of ordering a comfort care kit on admission to hospice allows access to 
anticipatory medications during unexpected symptomatic crisis.   
Consistent with the literature, this project identified that morphine is not the only 
medication needed in patients’ homes to relieve symptomatic crisis (Wowchuk et al., 
2009). Multi-symptom medication management is critical during the end of life 
transition.  Morphine relieves symptoms including pain and dyspnea.  Chau, Walker, Pai, 
and Cho (2008) identified the challenge due to alterations in opiate pharmacokinetics that 
occur with physiologic aging.  However, it does not address all the unexpected symptoms 
that occur with hospice patients during their final days.  According to Bishop and 
colleagues (2009) noisy secretions and fever were additional symptoms identified; 
medications used were an anticholinergic for secretions, such as atropine or 





scopolamine, and scopolamine derivatives improved patient outcomes when utilized to 
provide relief for symptomatic crises caused by noisy secretions (Kintzel et al., 2009).  
Anxiety has been identified as a problematic symptom frequently experienced during the 
end-of-life transition and has been associated with decreased quality of life in hospice 
patients.  Part of multi-symptom management includes managing anxiety with 
benzodiazepines.   The data from this study identified the most common utilized 
benzodiazepine to address anxiety was the pharmaceutical oral Ativan. 
5.2 Recommendations for Policy 
 
CMS requirements for hospice organizations are continuously expanding and the 
hospice organizations are being required to report on performance measure scores.  It is 
essential that hospice organizations have comfort care kits in place to improve quality of 
care and patient outcomes.  Hospice organizations need to strategically plan to avoid any 
decrease in Medicare reimbursement payments.  Hospice organizations must stay up-to-
date on evidenced-based research to continuously improve the delivery of healthcare 
provided to their patient population and enhance performance measures scores.   
In 2017, all hospice organizations throughout the United States are federally 
mandated to hire a third-party organization to administer surveys to the family members 
and caregivers of hospice patients after discharge.  The surveys are federally mandated 
beginning in 2017 and focus on the delivery of care and the overall hospice 
organization’s performance.  According to the NHPCO (2014), the CAHPS, a post-death 
family caregiver survey developed by CMS for the assessment of patient and family 
experiences with hospice care includes the following topics: hospice team 





emotional support; getting help for symptoms; getting hospice care training; providing 
support for religious and spiritual beliefs; information continuity; and understanding the 
side effects of pain medication.   
Today’s healthcare system holds hospice organizations more accountable for their 
delivery of care utilizing performance measurements including symptom management.  
The performance results impact hospice organizations not only financially, but also 
through a marketing aspect potentially affecting hospice patient referral rates for other 
healthcare providers.  These patient satisfaction rankings will be made accessible to the 
public, holding healthcare organizations even more accountable for improved patient 
outcomes.   
Improved scores on performance measurements allot hospice organizations the 
ability to avoid financial deficit in Medicare reimbursement dollars.  Reinforcing the 
implementation of comfort care kits on admission could alleviate poor score measures 
specifically on the symptom management performance rankings.  These public rankings 
can sustainably affect hospice organizations marketing strategies and overall professional 
reputations.     
 
5.3 Recommendations for Education 
 
In order to maintain comfort for the patient during the end-of-life transition, 
research shows that it is critical for hospice clinicians to continuously educate the patient 
and caregivers regarding the prognosis and therapeutic interventions.  Moreover, hospice 
clinicians must be educated on the full scope of multi-symptom management and 





Hospice staff must provide education regarding how patients can lose their ability 
to swallow during imminent death and how proper delivery of medication has a serious 
impact on the patient’s overall symptom management during the end-of-life transition.  It 
is essential that hospice organizations continuously educate their providers, family 
members, and caregivers on the utilization or initial steps when accessing medications 
from a comfort care kit.  This systematic procedure can be reinforced with educational 
handouts, assistance with caregiver’s first medication administration from kit, and 
continuous verbal education at each patient encounter. 
Finally, hospice clinicians must receive adequate education and training on 
critical aspects of assessments of hospice patients, especially as hospice patients’ 
transition to end of life.  Clinicians must be able to recognize signs and symptoms of 
imminent death in order to prepare both the patient and their loved ones.  Since hospice 
patients have a prognosis of six months or less to live, imminent death or decline can 
occur at any moment.  Caregivers and clinicians must anticipate the full scope of 
medication requirements to manage multi-symptoms that commonly occur during the 
end-of-life transition phase.   
5.4 Recommendations for Research  
 
Additional recommendations for further research in hospice includes the 
following: individualized comfort care kits, strategic processes to improve patient 
satisfaction measurements, and further analysis of the access to comfort care kits to rural 
hospice patients.  Further research is needed to illustrate that comfort care kits should be 
individualized based on the patient’s end-of-life diagnosis.  Some cancer patients require 





Evidence indicated that in cognitively impaired end-of-life patients, haloperidol is the 
most effective medication for treating agitation in patients.  Additional research is needed 
to implement diagnosis-specific comfort care kits individualized to the patient’s 
prognosis. 
Increasing patient involvement in research to improve the quality of care during 
the end-of-life transition will help to fill additional gaps of knowledge.  This is a 
vulnerable population to obtain data from due to their prognosis of death.  However, it is 
essential to promote quality improvement interventions without subjecting hospice 
patients to cumbersome questions or creating an uncomfortable environment for them.  
An approach to allow hospice the opportunity to complete a survey or provide input when 
cognitively able and on a complete volunteer basis.  A significant area of further research 
is the availability of medications, response rate of hospice organizations, and overall cost 
accrued delivering care to rural patients experiencing discomfort during the end-of-life 
transition. 
Future research in the hospice healthcare delivery system should focus on 
avoidable end-of-life side effects caused by all medications, specifically focusing on 
opioids in the elderly population during the end-of-life transition.  Opioids can cause 
distressful side effects in alert hospice patients taking their right to a dignified death.  
Patients verbally express their concerns of being in sound mind if able during their last 
days of life.  In the geriatric population morphine and other opioids can cause distressful 
symptoms.  According to Chau et al. (2008), the significance for healthcare providers 
prescribing opiates in the geriatric population is to utilize special considerations and 





of prescribing medication, potential side effects, and the comfort in use of opiates to treat 
patient symptoms (Zerzan et al., 2010).   
5.5 Limitations 
The quality improvement project underscores the need for multi-symptom 
management, which is consistent with the evidence based literature.  The data obtained 
were from healthcare providers at the frontline of this end-of-life care specialty both rural 
and urban areas.   
In terms of limitations, the sample size was relatively small (n = 23 pre and n = 23 
post survey) and all healthcare participants practice in the southern state of South 
Carolina.  There was a high response rate considering thirty participants were 
administered both pre-test and post-test with only twenty-three response rate with the pre-
test survey and twenty-three response rate with the post-test survey.  The length of time 
for the project was a significant limitation to this study, allotting the participants only one 
month for participants to respond to the surveys.  Finally, responses were not paired.  So 
it is possible a participant responded to the pre-survey but not the post-survey.   
5.6 Conclusion 
Ordering comfort care kits on admission is a quality improvement intervention for 
hospice patients, especially during an unanticipated symptomatic crisis.  Comfort care 
kits are a conglomerate of essential medications located within a sealed pharmacy bag or 
container.  These medications are utilized to alleviate distressful symptoms that 
commonly occur during the final phases of the dying process.  A licensed physician must 
write a hard copy prescription for the Comfort Care Kit because various medications are 





sequestered in the patient’s refrigerator until symptoms arise.   
Patients diagnosed with life-limiting conditions deserve the best delivery of 
comprehensive comfort care.  Evaluation of evidenced-based practice can identify best 
practice measures to improve symptoms in this population.  Implementation of comfort 
care kits into hospice patients’ homes can reduce suffering by both patients and their 
caregivers during unmanageable symptom crisis.  Oral morphine is a beneficial 
medication to address symptoms of both pain and dyspnea in hospice patients.  The 
anticholinergic medications deliver an improved patient outcome by alleviating increased 
secretions and nausea in patients during end-of-life care.  Continuous caregiver education 
is imperative to understanding the symptoms and therapeutic interventions that can 
provide relief to hospice patients.  Lastly, comfort care kits are a cost-effective approach 
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Scottish Intercollegiate Guidelines Network (SIGN) Grading System 1999–2012 
Levels of evidence 
1++ High quality meta-analyses, systematic reviews of RCTs, or RCTs with a very 
low risk of bias 
1+ Well-conducted meta-analyses, systematic reviews, or RCTs with a low risk of 
bias 
1- Meta-analyses, systematic reviews, or RCTs with a high risk of bias 
2++ High quality systematic reviews of case control or cohort or studies 
High quality case control or cohort studies with a very low risk of confounding 
or bias and a high probability that the relationship is causal 
2+ Well-conducted case control or cohort studies with a low risk of confounding or 
bias and a moderate probability that the relationship is causal 
2- Case control or cohort studies with a high risk of confounding or bias and a 
significant risk that the relationship is not causal 
 
3 Non-analytic studies, e.g. case reports, case series 









Michigan Quality Improvement Consortium (2008) 
 
Definitions: Levels of Evidence for the Most Significant Recommendations 
 
A. Randomized Controlled Trials 
 
B. Controlled Trials, Non-Randomized (Case Study and Cohort Study) 
 
C. Observational Studies (Descriptive Studies) 
 
D. Expert Panel  














Symptom Management Model 
 
 












Comfort Care Kit Handout 
Common End of Life Signs and Symptoms 
Common multi-symptoms among hospice patients are pain, dyspnea, nausea, delirium, 
and increased secretions.  According to Morrow (2014) anxiety and insomnia are 
additional distressful symptoms experienced by patients during the end of life transition.   
Comfort Care Kit 
Definition 
A Comfort Care Kit is a conglomerate of essential medications located within a sealed 
pharmacy bag or container.  According to Morrow (2014) the hospice comfort kit is also 
referred to as the emergency kit contains a prescribed set of medications to assist the 
hospice team in treating distressful symptoms as soon as possible.  These medications are 
utilized to alleviate distressful symptoms that commonly occur during the final phases of 
the dying process.  A licensed physician must write a hard copy prescription for the 
Comfort Care Kit, various medications are controlled substances.  Once the Kit is 
delivered to the patient’s residence it remains sequestered in the patient’s refrigerator 
until symptoms arise.     
Comfort Care Kits Contents 
Morphine used to address pain, shortness of breath, and dyspnea. 
Haloperidol, Lorazepam, or other Benzodiazepine used to alleviate anxiety or 
restlessness, and insomnia (Morrow, 2014).  
Metoclopramide to treat nausea or increased gastric secretions. 
Scopolamine used to treat nausea or increased secretions. 
Phenergan used to treat nausea or vomiting.  
Atropine used to treat increased respiratory secretions, also known as the death rattle 
(Morrow, 2014). 
Acetaminophen or Ibuprofen used to alleviate terminal fever or pain. 







Pre-Test and Post-Test Survey 
 
Table E.1. 
Multiple Choice Questions  
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Medication kits for managing 
symptomatic emergencies 
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JOURNAL OF PALLIATIVE 
MEDICINE 
Volume 12, Number 1, 2009 
 
The study identified a decreased 
amount of research available that 
focused on hospice programs’ 
utilizing medication kits 
(comfort kits).  Comfort care kits 
are used for the purpose of 
managing hospice patients’ 
uncontrolled symptoms at home 







They conducted a 
telephone survey 
of all 22 agencies 
in New Hampshire 
providing home 
hospice care.  
Most respondents  
surveyed inquired 
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and perceived 
impact of kits.  
The survey was 
administered by 
phone interview.   
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Reporting 





treat pain and 
dyspnea, 81% for 
nausea and 
vomiting, 
and 76% for 
seizures. Eighty-
six percent of 
agencies (18/21) 
reported that a 
medication within 
the kits was used 
in more than 50% 
of cases. Eighty-
six percent 







hospice and palliative 
care patients is the 
essential purpose of 
these establishments.  
Hospice programs are 
established to provide 
quality care and 
comfort to their 
patients, allowing 
them a dignified 
dying experience.    
Hospice programs 
commonly utilize kits 
containing 
prescription 
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hospice 
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The survey 
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dispensed.   
visits. Oral, 
sublingual, and 
rectal routes of 
administration 








morphine in kits. 
Kits cost less than 
$50 for the 
majority 
of programs. 
home. There is 
considerable variation 
in kit contents and 
practice. 
Programs believe that 
kits diminish 
emergency 
department visits and 
hospitalizations. 
Research is needed to 
more fully describe 
and study the 
outcomes of these 
practices. 
Currow, D.C., Vella-Brincat, J., 
Fazekas, B., Clark, K., Doogue, 





cohort of patients 
from 12 
Reporting 
bias due to 
the study 
Of the 53 people 
included in the 
cohort, 23 (43%) 
Overall, one in three 
people gained net 
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Rapid Report of Net Clinical 
Effect of Metoclopramide 
 
 
JOURNAL OF PALLIATIVE 
MEDICINE 
Volume 15, Number 10, 2012 
 
The aim of this study was to 
describe the clinical effect of 
metoclopramide when prescribed 
routinely in a consecutive, 
prospective cohort of 









initiated had data 
collected at three 
time points—
baseline, 2 days 
(clinical benefit), 
and day 7 
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bias due to 
its relatively 
small 
sample size.   
 
reported benefit 
at 48 hours, but 
only 18 (34%) of 
these 
people were still 
using it one week 
after commencing 
it. For the other 5, 
the medication 




were akathisia (n 
= 4), headache (n 
= 4), and 
abdominal pain 
(n = 4). Nine 
people (17%) 




week. Limiting effects 
include side effects 
that needs to be 
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Currow, D.C., Rowett, D., 
Doogue, M., To, T.H., & 
Abernethy, A.P. 
 
An international initiative to 
create 
a collaborative for 
pharmacovigilance in hospice 
and palliative care clinical 
practice 
 
JOURNAL OF PALLIATIVE 
MEDICINE 
Volume 15, Number 3, 2012 
 
 
There is a need for prospective, 
systematic 
pharmacovigilance in hospice 














net clinical benefit 
and safety of 
common 
medications. The 
intention is for a 
diverse and large 
group of clinical 
units to record data 
prospectively on a 
small identified 
consecutive cohort 
of patients started 
on the medication 
of interest. A new 
medication would 
be studied every 3 
months. Three key 
time points 
(different for each 
medication) will 
be assessed for 
N/A N/A 









The intention is to 
create an efficient, 
relevant system to 
improve hospice and 





project will include a 
simple registry 
format, medications 









longitudinal data to 
complement short-
term efficacy data 
generated for 
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codefiable data at 
baseline, a 
point at which 
clinical benefit 
should be 
experienced, and a 
point at which 
short- to medium-
term toxicities may 
occur. Toxicities 
can additionally be 
recorded at any 
time they occur. 
Data collection 
will take a 




Of the nine 
criteria proposed 
by Naranjo and 
colleagues to 
attribute 
causality to a 
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adverse event, five 
will be 
used in the clinical 
assessment to aid 
in understanding 
likely 
attribution of a 
relationship 
between the 
medication and the 
observed side 
effect (Table 1). 
Those that will be 
omitted are not 
realistic for routine 
use in end-of-life 
care.  
Kintzel, P.E., Chase, S.L., 
Thomas, W.,  Vancamp, D.M.,  
& Clements, E.A.  
 
Anticholinergic medications for 
managing noisy 
respirations in adult hospice 
patients 
 
Am J Health-Syst Pharm—Vol 
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Maltoni, M.,  Miccinesi, G., 
Morino, P., Scarpi, E., Bulli, F.,  
Martini, F., Canzani, F., 
Dall’Agata, M., Paci, E., & 
Amadori, D.  
 
Prospective observational Italian 
study on palliative sedation 
in two hospice settings: 
differences in case mixes 
and clinical care 
 




The purpose of this study 
identified Palliative sedation 
(PS) has been defined as the use 
of sedative medications to 
relieve intolerable suffering from 
refractory symptoms by a 
reduction in patient 
consciousness. 
It is sometimes necessary in end-










conducted over a 
period of 9 months 
on 327 patients 
consecutively 
admitted to two 
11-bed Italian 
hospices (A and B) 
with 
different case 
mixes in terms of 
median patient age 
(hospice A, 
66 years vs. 
hospice B, 73 
years; P00.005), 
mean duration of 
hospice stay 
(hospice A, 13.5 
days vs. hospice B, 
18.3 days; 
P00.005), and 
death rate (hospice 
Reporting 
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Geographic
al bias due 
to study 
participants 







higher in hospice 








(RASS, -5) was 
necessary in only 
58.3% of sedated 
patients. Average 
duration 
of sedation was 
similar in the two 




PS represents a highly 
reproducible clinical 





results. It does not 
have a detrimental 
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present refractory symptoms. We 
investigated PS for refractory 
symptoms in different hospice 
case mixes in order to (1) 
assess clinical decision-making, 
(2) monitor the practice of 
PS, and (3) examine the impact 




A, 57.2% vs. 
hospice B, 
89.9%; P<0.0001). 








22% of the total 
admissions and 
31.9% of deceased 
patients, which did 
not prove to be 
significantly 
different in 
the two hospices 
after adjustment 






with a trend in 
favor of sedated 
patients.   
Mercadante, S., Villari, P., & 
Casuccio, A.   
 
An Italian survey on the attitudes 
in treating 
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al bias due 
to study 
participants 
from Italy.    








suggest the need for 
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The aim of this study was 
to assess the knowledge and 
attitudes of hospice physicians 
in Italy regarding BcP and its 




statistics, and the 
Chi-square test.  
All hospices 




about provision of 
BP medication, 
drugs of choice, 
preferred route of 
administration, 
methods to choose 
the 
dose, and choice of 
BcP medication 
based on opioid 
administered for 
background 
analgesia.   
Morphine was 
more frequently 
















opioid or the 
route of 
administration. 
The choice of 
dose titration was 
equally 




BcP, particularly in a 
potentially specialized 
setting, such as 
palliative care units. 
The choice of BcP 
medications should 
be based on the best 
cost-efficacy ratio 
rather than solely on 
economic 
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medication on the 
basis of opioid 
basal regimen 
was equally 
distributed.   
Rose, M. & Currow, D.C.  
 
The need for chemical 
compatibility Studies of 
subcutaneous medication 
combinations used in palliative 
care 
 
Journal of Pain & Palliative Care 






The purpose of this study was to 
optimize symptom control in 
those patients who can take 
medications orally and in those 




Rating-  4 
 
 




care delivery is 
by quality 
laboratory 
data to underpin 
best practice (p. 
228).   
Given the 
widespread use of 
injectable 
combinations 
in hospice and 
palliative care, 
there is an 
urgency to define 
best practice 
There is an urgent 
need to attract 
funding so that a 
systematic body of 
work 
can commence that 






practice on a daily 
basis. This may 
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therefore, requiring an 
alternative route of 
administration.  If transdermals, 
intranasal, nebulized, rectal, or 
sublingual route of medication 
administration are not valid 
routes, the subcutaneous 
administration of medication can 




















Sera, L., McPherson, M. L., & 




medications in a population of 
hospice patients. American 
Journal of Hospice and Palliative 







Data for this study 
were provided by 
Seasons Hospice 
& Palliative Care, 
a national hospice 
organization with 
locations in 11 
states at the 
time of the study 
(currently in 15 
Sample Bias 









The 100 most 
commonly 
prescribed drugs 
are listed in Table 
3. 





This study of patients 
admitted for hospice 
care with any 
diagnosis 
revealed that 
medications used to 
treat common end-of-
life 
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The purpose of this study was to 
determine the most commonly 
prescribed medications in a 
population of hospice patients. 
states). The 
clinical 
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The palliative medication kit: An 
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death.  
 
Journal of Palliative Medicine, 




Palliative medication kits for 
home use were developed in 
order to extend the period of 
time terminally 
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complete 
a data collection 
form each time 
they accessed the 
PMK and to 
submit completed 
forms to the 
palliative care 
program for 










included.   
From 2002–2007, 
a total of 293 kits 
were placed in 
patients’ homes 




died at home, 
compared to 24% 
who died outside 
of an acute care 
setting across the 
entire 
program 
(w2¼579.71; p < 
0.0001). In 2006–
2007, 73 kits 





compared to a 
program home 
death rate of 27% 
(w2¼60.70; p < 
0.0001). 
Palliative medication 
kits are a simple and 
effective way of 
anticipating and 
addressing comfort 
and symptom control 
for dying patients 
being cared for in the 
community. These 
kits can avert 
institutional 
crisis admissions, 
extend the period of 
time patients can be 
cared for in their 
homes and may 
increase the 
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in end-of-life care 
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The aim of this study sought to 
explore variation in approaches 
to pharmaceutical management 
of pain among hospice-eligible 
patients and to determine if 
variation was explained by 
patient or site of care 
characteristics. Variation in 
medication use may suggest 
areas for best practices or quality 
improvement in medication use 





They conducted a 
secondary analysis 
of randomized trial 
data, examining 
































reported.   
Found variation 
in medication use 
was not predicted 









age (odds ratio 




sites: a range of 
14%–83% of 
patients were on 





Pain and adjuvant 
medication use differs 
widely by site of care. 
Further research is 
needed to 
determine the extent 
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0%–23% were on 
acetaminophen at 
any time during 
the data 
collection period.   
 
 
 
 
 
 
 
